

**WEILL CORNELL MEDICAL COLLEGE CURRICULUM VITAE FORM**

(REQUIRED FORMAT)

Signature (required):	<i>Karla V. Ballman</i>
Version date:	7 June 2019

**A. GENERAL INFORMATION**

**Required Information:**

Name: First, Middle, Last	Karla V. Ballman
Office address:	Healthcare Policy and Research LA-225 Weill Cornell Medical College 402 East 67 <sup>th</sup> Street New York, NY 10065
Office telephone:	646-962-8023
Office fax:	646-962-0281
Home address:	430 East 63 <sup>rd</sup> Street Apt. 12G New York, NY 10065
Home telephone:	507-301-3013
Cell phone:	507-301-3013
Beeper:	N/A
Work Email:	<a href="mailto:kab2053@med.cornell.edu">kab2053@med.cornell.edu</a>
Personal Email:	<a href="mailto:kvballman@gmail.com">kvballman@gmail.com</a>
Citizenship:	USA
If not a U.S. Citizen, do you have:	Immigrant visa (green card)? Non-immigrant Visa? Type:

**Optional Information (not required but helpful):**

Birth date:	11/14/1960
Birth place:	St. Cloud, MN

Marital status:	Divorced
Race/Ethnicity:	Caucasian

**B. EDUCATIONAL BACKGROUND**

1. Academic Degree(s): B.A. and higher; institution name and location; dates attended; date of award. Expand the table as needed.

Degree (abbreviation)	Institution Name and Location	Dates attended	Year Awarded
B.A.	Macalester College St. Paul, MN	9/1979 to 5/1983	1983
Scientiæ Magister (S.M.)	Massachusetts Institute of Technology Cambridge, MA	9/1985 to 6/1991	1989
Ph.D.	Massachusetts Institute of Technology Cambridge, MA	9/1985 to 6/1991	1991

2. Post-doctoral training (include residency/fellowships): In chronological order beginning with post-doctoral training positions; include full titles, ranks and inclusive dates held. Expand the tables as needed.

**N/A**

3. Continuing Medical Education Courses/Certificates

**N/A**

4. Other Educational Experiences

**N/A**

**C. LICENSURE, BOARD CERTIFICATION, MALPRACTICE**

1. Licensure: Every physician appointed to the Hospital staff, except interns, and aliens in the US via non-immigrant visas, must have a New York State license or a temporary certificate in lieu of the license.

**N/A**

2. Board Certification

**N/A**

3. Malpractice Insurance

**N/A**

#### D. PROFESSIONAL POSITIONS AND EMPLOYMENT

##### 1. Academic positions (teaching and research)

Title	Institution name and location	Dates held
Assistant Professor of Mathematics and Computer Science	Macalester College St. Paul, MN	8/1991 to 6/1999
Lecturer of Statistics	University of Auckland Auckland, New Zealand	1/1994 to 7/1996
Assistant Professor of Biostatistics	Mayo Clinic College of Medicine Rochester, MN	12/1999 to 7/2001
Associate Professor of Biostatistics	Mayo Clinic College of Medicine Rochester, MN	7/2001 to 10/2007
Adjunct Associate Professor of Biostatistics	University of Minnesota Minneapolis, MN	9/2007 to 7/2015
Adjunct Associate Professor	Biomedical Informatics and Computation Biology, University of Minnesota Rochester Rochester, MN	9/2010 to 7/2015
Professor of Biostatistics	Mayo Clinic College of Medicine	11/2014 to 7/2015
Professor of Healthcare Policy and Research Tenure awarded (11/2016)	Weill Cornell Medical College New York, NY	7/2015 to present

##### 2. Hospital positions (e.g., attending physician)

N/A

##### 3. Other Employment

Title	Institution name and location	Dates held
Actuarial Trainee	Minnesota Mutual Life Insurance Company St. Paul, MN	1983 to 1985
Consultant	AT&T Bell Labs Software Production Research Naperville, IL	1991 to 1994
Research Associate	Division of Biostatistics, Department of Health Sciences Research, Mayo Clinic Rochester, MN	1999 to 2002
Senior Research Associate	Division of Biostatistics, Department of Health Sciences Research, Mayo Clinic Rochester, MN	2002 to 2004
Senior Associate Consultant	Division of Biostatistics, Department of Health Sciences Research, Mayo Clinic Rochester, MN	2004 to 2007

Senior Associate Consultant	Division of Biomedical Informatics Department of Health Sciences Research, Mayo Clinic Rochester, MN	2005 to 2007
Group Statistician	American College of Surgeons Oncology Group (ACOSOG) Statistics and Data Center Rochester, MN	2006 to 2014
Chair	Division of Biostatistics, Department of Health Sciences Research, Mayo Clinic Rochester, MN	2006 to 2008
Consultant	Division of Biostatistics, Department of Health Sciences Research, Mayo Clinic Rochester, MN	2007 to 2008
Consultant	Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic Rochester, MN	2008 to 2015
Associate Editor	Journal of Clinical Oncology	2010 to 2017
Deputy Editor	Journal of Clinical Oncology	2017 to present
Consultant	Department of Surgery, Mayo Clinic Rochester, MN	2012 to 2015
Director of Biostatistics	Alliance Statistics and Data Center Rochester, MN	2013 to 2015
Division Chief of Biostatistics and Epidemiology	Healthcare Research and Policy Weill Cornell Medical College New York, NY	07/2015 to present

**E. EMPLOYMENT STATUS (current or anticipated)**

Name of Employer(s): Weill Cornell Medical College
Employment Status (choose one, delete the others): Full-time salaried by Weill Cornell

**F. INSTITUTIONAL/HOSPITAL AFFILIATION**

N/A

## G. PERCENT EFFORT AND INSTITUTIONAL RESPONSIBILITIES

WCMC ANTICIPATED % EFFORT	(%)	Does the activity involve WCMC students/researchers? (Yes/No)
TEACHING	20%	yes
CLINICAL	0%	
ADMINISTRATIVE	40%	no
RESEARCH	40%	yes
TOTAL	100%	

### INSTITUTIONAL RESPONSIBILITIES

1. Teaching (e.g., specific teaching functions, courses taught, dates: For guidance refer to Teaching Metrics table. Report your teaching activities in the 4 areas of teaching shown below. To provide a more detailed teaching report, use the Teaching Activities Report template or Educator Portfolio template (strongly encouraged). Refer to it here as an attachment (e.g., see attached), and attach it to the CV.

<b>Didactic teaching:</b> (e.g., lectures, continuing medical education courses, grand rounds, professional development programs, seminars, tutorials)	
Protocol Development (tutorial leader, Mayo Clinic College of Medicine) Health Sciences Grand Rounds	Dates 2008-2012
<b>Mentorship:</b> (e.g., mentor for medical student, graduate student, resident, clinical or postdoctoral research fellow or junior faculty projects; service as graduate student thesis advisor or committee member)	
8 M.S. candidates in the Clinical Research Master's degree program (Mayo Clinic College of Medicine)	Dates 2004-2015
Served on five M.S. thesis committees for M.S. candidates in the Clinical Research Master's degree program (Mayo Clinic College of Medicine)	2004-2015
Thesis advisor to 4 students in the Biomedical Informatics and Computational Biology M.S. degree program	2012-2015
<b>Clinical teaching:</b> (e.g., teaching in the clinic or hospital including bedside teaching, teaching in the operating room, preceptor in clinic)	
	Dates
<b>Administrative teaching leadership role:</b> (e.g., residency or fellowship director, course or seminar director or co-director)	
Probability and Mathematical Statistics (course director, Macalester College)	Dates 1991
Introductory Statistics (course director, Macalester College)	1991, 1992
Mathematical Modeling (course director, Macalester College)	1991, 1992
Calculus II (course director, Macalester College)	1992
Calculus III (course director, Macalester College)	1992
Applied Probability (course director, Macalester College)	1992-1998
Mathematical Statistics	1993-1999

Stochastic Methods in Management Science (course director, University of Auckland)	1994-1996
Decision Analysis (course director, University of Auckland)	1994-1996
Data Analysis with R (course director, University of Auckland)	1994-1996
Statistics Minor Curriculum Development (Macalester College)	1994-1995
Elementary Statistics (course director, Macalester College)	1995-1996
Linear Algebra (course director, Macalester College)	1996-1998
Senior Capstone (course director, Macalester College)	1996
Applied Multivariate Statistics (course director, Macalester College)	1997-1999
Differential Equations (course director, Macalester College)	1998
Experimental Design and Data analysis (course director, Macalester College)	1998
Introductory Statistical Method I (course director, Mayo Clinic College of Medicine)	1999
Special Topics in Health Sciences Research (course director, Mayo Clinic College of Medicine)	2000-2003
Introductory Statistics Methods II (course director, Mayo Clinic College of Medicine)	2002, 2005
Clinical Trials (course director, Mayo Clinic College of Medicine)	2003-2004
Introduction to Biostatistics (course director, Executive MBA/MS program, Weill Cornell Medicine)	2010, 2011
Biostatistics I (course director, Biostatistics and Data Science MS program, Weill Cornell Medicine)	2017-present
	2018-present

2. **Clinical care (duties, dates):** To document clinical activities use the table below or, to document extensive clinical activities use the [Clinical Portfolio template](#) (strongly encouraged). Refer to it here as an attachment and attach it to the CV.

N/A

3. **Research (duties, dates):** Summarize research activities in the table below. Provide key contributions, and annotate key grants and publications or use a [Statement of Key Contributions](#). Refer to it here and attach it to the CV.

Research Activity / Key Contributions	Dates
See Statement of Key Contributions	

4. **Administrative Activities (duties, dates):** Describe administrative activities in the table below. To document administrative activities more extensively use a supplemental statement, refer to it here and attach it to the CV.

Administrative Activity	Date
Education Committee Member (Health Sciences Research, Mayo Clinic)	2000 to 2002
Education Committee Chair (Health Sciences Research, Mayo Clinic)	2002 to 2007
Education Committee Member (Clinical Research Training Program, Mayo Clinic)	2001 to 2006
Executive Committee Member (Clinical Research Training Program, Mayo Clinic)	2001 to 2005
Master's Examination Committee Member (Clinical Research Training Program, Mayo Clinic)	2002 to 2015
Curriculum Committee Chair (Clinical Research Training Program, Mayo Clinic)	2002 to 2006
Data Safety and Monitoring Board Member (Mayo Clinic Cancer Center)	2003 to 2006
Clinical Studies Oversight Committee Member (Mayo Clinic Cancer Center)	2003 to 2006
Neuro-Oncology Executive Committee Member (Mayo Clinic Cancer Center)	2003 to 2010
Neuro-Oncology Protocol Planning Committee Member (Mayo Clinic Cancer Center)	2003 to 2007
Education Committee Member (Mayo Graduate School)	2004 to 2006
Executive Committee Member (Department of Health Sciences Research, Mayo Clinic)	2004 to 2008
Education Programs Curriculum Committee Member (Center for Translational Activities, Mayo Clinic)	2006 to 2008
Division Chair (Division of Biostatistics, Health Sciences Research, Mayo Clinic)	2006 to 2008
Peer Review Research Committee Member (Department of Surgery, Mayo Clinic)	2011 to 2015

Research Executive Committee Member (Department of Surgery, Mayo Clinic)	2011 to 2015
Research Committee Member (Department of Surgery, Mayo Clinic)	2011 to 2015
Data Safety and Monitoring Board Member (Department of Surgery, Mayo Clinic)	2012 to 2015
Division Chief for Healthcare Policy & Research	2015 to present
Healthcare Policy & Research Promotions Committee Member	2015 to present
Weill Cornell Medicine Data Safety and Monitoring Board (alternative) Co-Chair	2017 to present
Weill Cornell Committee of Review	2018 to present

## H. RESEARCH SUPPORT

Summarize Past Research Support:

1. The Mayo Clinic Research Training Program funded by National Center for Research Resources (K30 RR 22296) from 06/1999 to 09/2006 ; role: Associate Director
2. Risk Factors for Venous Thromboembolism in the Community funded by NHLBI (R01 HL 66216) from 04/2001 to 04/2005; role: Co-investigator
3. Angiotensin-II Blockade in Mitral Regurgitation funded by NHLBI (R01 HL 64928) from 04/2001 to 03/2005; role: Co-investigator
4. Core 1: Statistical and Administrative Core in: Gene Therapy for Vaso-occlusive disease funded by NHLBI (P01 HL 66958) from 09/2001 to 08/2008; role: Co-investigator
5. Core B: Study Design and Analysis Core in: Molecular Markers of Glioma Initiation & Progression funded by NCI (P01 CA 85799) from 06/2001 to 05/2006; role: Principal Investigator
6. GSK-3 and Associated Pathways in PNET funded by NINDS (R01 NS 40794) from 07/2002 to 11/2005; role: Collaborator
7. Mitochondria and surgical myopreservation in aging funded by NIA (R01 AG 21201) from 09/2002 to 08/2008; role: Consultant
8. Heart Failure in the Community funded by NHLBI ((R01 HL 72435) from 01/2003 to 06/2007; role: Co-investigator
9. Flavopiridol as a Potential Therapy in Multiple Myeloma funded by NCI (R01 CA 98118) funded from 07/2003 to 06/2008; role: Co-investigator
10. MAGE-A3/HPV 16 Peptide Vaccines for Head and Neck Cancer funded by the NIDCR (R01 DE 15324) from 04/2004 to 12/2004; role: Co-investigator
11. Xenograft Model for Studying Amplified EGFR in GBM funded by NCI (R01 NS 49720) from 08/2004 to 05/2006; role: Co-investigator
12. Brain Tumor SPORE – Core B – Biostatistics funded by NCI (P50CA 108961) from 09/2004 to 08/2014; role: Core Director
13. Global Differential Expression Profiling During Sudden Tumor Progression Using the Tumor Dedifferentiation Phenomenon as a Model funded by Mayo Clinic Foundation (CR20) from 04/2006 to 06/2010; role: Co-investigator
14. Measles Virotherapy for Glioblastoma Multiforme funded by NCI (R21 CA 123839) from 08/2006 to 07/2010; role: Co-investigator
15. Utility of Serum and Tissue Biomarkers for Predicting Response to Androgen Deprivation Therapy in the Population of Men with Rising PSA Following Definitive Treatment in: SPORE in Prostate Cancer funded by NCI (P50 CA 91956) from 09/2006 to 08/2013 ; role: Co-investigator
16. SPORE in Prostate Cancer—Biostatistics Core funded by NCI (P50 CA 91956) from 09/2006 to 08/2013; role: Core Director
17. Statistical Responsibilities for American College Of Surgical Oncology Group (ACOSOG) funded by NCI (U10 CA 76001) with subcontract to Mayo from 03/2006 to 11/2014; role: Principal Investigator
18. Epigenetic regulation of temozolomide responsiveness in glioblastoma funded by NCI (R01 CA 127716) from 01/2008 to 12/2012; role: Co-Investigator
19. Correlative Science and Imaging Analysis for Z1031 funded by Breast Cancer Research Foundation (WU-09-200) with subcontract to Mayo from 10/2008 to 09/2009; role: Principal Investigator
20. A phase III randomized Double Blind study of Adjuvant ST1571 (Gleevee) versus Placebo in patients following the Resection of primary gastrointestinal Stromal Tumor (GIST) funded by Novartis from 12/2008 to 06/2009; role: Principal Investigator
21. Mayo Comprehensive Cancer Center Grant funded by NCI (P30CA 15083) from 03/2009 to 07/2015; role: Statistician

22. Novel Biomarkers for Aromatase Inhibitor Therapy funded by NCI (R01 CA 95614) from 04/2009 to 12/2011; role: Principal Investigator
23. Optimizing Measles Virotherapy in the Treatment of Gliomas funded by NCI (R01CA 140620) from 07/2009 to 03/2011; role: Co-investigator
24. ACOSOG Community Clinical Oncology Program (CCOP) Research Base funded by NCI (U10CA 149950) from 06/2010 to 07/2014; role: Co-investigator
25. Treatment patterns of patients with newly diagnosed malignant primary brain tumors funded by Monteris Medical from 09/2010 to 08/2011; role: Principal Investigator
26. Statistical Responsibilities for American College Of Surgical Oncology Group (ACOSOG) in: Industry Supplement of Statistical Responsibilities for American College Of Surgical Oncology Group (ACOSOG) funded by Duke Clinical Research Institute from 12/2010 to 11/2011; role: Principal Investigator
27. N1037 P95HER2 expression in metastatic breast cancer patients treated with trastuzumab on N0337 and NCCTG 98-32-52 funded by BioTheragnostics/BioMerieux from 10/2011 to 3/2012; role: Co-investigator
28. Part 1 N9831F-NCCTG-ICSC Validation study of Quantitative Single Gene Assessment of HER2 mRNA by qRT-PCR and Development and Testing of New HER2 Multi-Gene Signature funded by Genomic Health, Inc. from 04/2012 to 05/2015; role: co-Principal Investigator
29. Therapeutic Strategy to Slow Progression of Calcific Aortic Valve Stenosis funded by National Center for Advancing Translational Sciences (UH2TR 000954) fro 06/2013 to 07/2015; role: Co-investigator
30. Patient Centered: Risk Stratified Surveillance After Curative Research of Colorectal Cancer funded by a subcontract from a PCORI grant (CE-1304-6855) from 03/2014 to 07/2015; role: Principal Investigator
31. Post-Treatment Surveillance in Breast Cancer: Bringing CER to the Alliance funded by a subcontract from a PCORI grant (CE-1304-6543) from 03/2014 to 07/2015; role: Principal Investigator
32. Statistics and Data Center for the Alliance for Clinical Trials in Oncology funded by NCI (U10CA 180882) from 04/2014 to 07/2015; role: Co-investigator
33. Alliance NCORP Research Base funded by NCI (UG1CA 189823) from 08/2014 to 07/2015; role: Co-investigator
34. Improving How We Predict Toxicity for Older Women with Breast Cancer funded by Susan G. Komen Breast Cancer Foundation from 10/2014 to 09/2017; role: Principal Investigator (subsite)
35. Sarcoma Foundation from 11/2015 to 05/2017; role: Principal Investigator
36. Clinical and Translational Science Center (2UL1 TR000457) funded by NIH from 06/01/12 to 05/31/17; role: Co-Investigator
37. SPECS Grant in Lung Cancer (U01CA 157715) funded by NCI from 07/2012 to 06/2018; role: PI of a subcontract
38. Sarcoma SPORE—Biostatistics Core funded by NCI (5U54CA 168512) from 09/2016 to 08/2018; role: Core Director
39. Prostate Cancer Foundation study funded from 07/2017 to 08/2018; role: co-investigator

For **Current extramural and intramural research funding**, provide the following for each award:

1. Source, amount, and duration of support (dates)
2. Name of Principal Investigator
3. Individual's role in project, including percentage (%) effort

**Current Research Support** (duplicate table as needed):

Source	NCI (CA180882) subcontract Alliance
Amount	\$172029
Duration	04/2018 to 02/2023
Principal Investigator	Mandrekar
Your Role in Project	Co-investigator (PI of the subcontract to WCMC)
% Effort	40%

Source	SU2C
Amount	\$13,515

Duration	08/2017 – 06/2020
Principal Investigator	Cantley
Your Role in Project	Co- Investigator
% Effort	5%

Source	National Institutes of Health 1UL1TR002384-01
Amount	\$5,319,707
Duration	09/2017 to 06/2022
Principal Investigator	Imperato-Mcginley
Your Role in Project	Co-Investigator
% Effort	6%

Source	Department of Defense (Subcontract with Duke University, W81XWH-17-1-0372)
Amount	\$170,266
Duration	11/2017 to 10/2020
Principal Investigator	Harpole
Your Role in Project	Principal Investigator (Subsite)
% Effort	10%

Source	National Institutes of Health (P50 CA211024-01A1)
Amount	\$134,759
Duration	07/2017 to 06/2022
Principal Investigator	Rubin
Your Role in Project	Computational Biology and Biostatistics Core Director
% Effort	3%

Source	Bill and Melinda Gates Foundation
Amount	\$89,116
Duration	11/2016 to 05/2020
Principal Investigator	Lee
Your Role in Project	Investigator
% Effort	2%

Source	NIMH, ALACRITY for late- and Mid-Life Mood Disorders (P50 MH113838)
Amount	\$1,014,850
Duration	09/2016 to 08/2021
Principal Investigator	Alexopoulos
Your Role in Project	Investigator
% Effort	5%

Source	NIH, Biomarkers of taxane chemotherapy response/resistance in prostate cancer (R21 CA216800-01A1)
Amount	\$130,500
Duration	04/2018 to 03/2020
Principal Investigator	Giannakakou

Your Role in Project	Investigator
% Effort	2%

Source	Department of Defense, Molecular and clinical correlates with prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (W81XWH-17-PCRP-IA)
Amount	\$72,380
Duration	07/2018 to 06/2021
Principal Investigator	Tagawa/Beltran/Bander
Your Role in Project	Investigator
% Effort	2%

Source	NIH/NCI, Mechanism-based Targeting of Mantle Cell Lymphoma (P01 CA2144274-01A1)
Amount	\$1,166,145
Duration	09/2018 to 08/2023
Principal Investigator	Chen-Kiang
Your Role in Project	Core Leader
% Effort	8%

Source	NIH, The human distal airway aging project (U01HL145561)
Amount	\$5,688
Duration	01/19-12/2024
Principal Investigator	Shaykhiev
Your Role in Project	Biostatistician
% Effort	3%

#### I. EXTRAMURAL PROFESSIONAL RESPONSIBILITIES

i.e. – Journal Reviewer, Editorial Boards, Study Sections, Invited Presentations

Activity / Responsibility	Dates
Reviewer The American Math Monthly	1991 to 1999
Gender and Ethnic Division Committee Member North Central Cancer Treatment Group	2002 to 2005
Neuro-Oncology Committee Member North Central Cancer Treatment Group	2002-2006
Reviewer The American Statistician	1994 to 1999
Editorial board member Journal of Statistics Education	1998 to 2003
Reviewer Mayo Clinic Proceedings	2001 to 2004
Reviewer Circulation	2003 to 2006
NCI Review Panel Member Consortium Therapeutic Studies of Primary Central Nervous System Malignancies in Adults	2003, 2008
Reviewer Bioinformatics	2004 to present

NCI Study Section ad hoc Member Scientific Review Group Subcommittee H-Clinical	2004, 2007, 2008
Reviewer Cancer Research	2004 to present
Editorial Board Neuro-Oncology	2004-2014
Reviewer American Journal of Gastroenterology	2005 to 2006
Review Panel Member Academic Public-Private Partnership Program (AP4)	2005
NCI-Avon Foundation Review Panel Member PFP Awards Program	2005 to 2006
NCI Review Panel Member Advanced Proteomic Platforms and Computation Sciences for the NCI Clinical Proteomic Technologies Initiative Review Panel	2006
Executive Committee Member American College of Surgeons Oncology Group	2006 to 2012
NCI Committee Member Breast Cancer Intergroup Committee	2007 to 2009
NCI Committee Member Breast Cancer Intergroup Correlative Sciences Committee	2008 to 2009
NCI Study Section Member Scientific Review Group Subcommittee H-Clinical	2009 to 2012
NCI Steering Committee Member Gastrointestinal Stromal Tumor Working Group	2009-2013
NCI Steering Committee Member Brain Malignancies	2009 to present
NCI Review Panel Member Novel Methodologies	2006
Data Monitoring Committee Member American College of Surgeons Oncology Group	2006 to 2011
Breast Cancer Committee Lead Statistician American College of Surgeons Oncology Group	2006 to 2011
Reviewer Biometrics	2006
NIAID Review Panel Member Cooperative Study Group for Autoimmune Disease Prevention	2006
Clinical Scientific Review Committee Member American College of Surgeons Oncology Group	2006 to 2011
Reviewer International Journal of Cancer	2006 to present
NICHHD Review Panel Member Obstetrical Pharmacology Research Network-Data Coordination and Analyses Center (OPRU-DCAC)	2007
Canada Cancer Society Review Panel Grant Application Review	2007
Editorial Board Journal of Clinical Oncology	2007 to 2010
NIAID Review Panel Member Proteomics Centers for Infectious Diseases and Biodefense	2008
NIDDK Review Panel Member Hepatitis B Clinical Research Network (U01)	2008
NIH Review Panel Member Data Management and Coordinating Center DMCC for the Rare Diseases Clinical Research Network (RDCRN)	2008
NIDDK Review Panel Member Multi-disciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network (U01)	2008
Data Monitoring Committee Member	2008-2012

Astra-Zeneca Phase III Trial	
Reviewer EURASIP Journal on Bioinformatics and Systems Biology	2008 to present
NCI Committee Member Clinical Trials Advisory Committee, Operational Efficiencies Working Group	2008 to 2009
NICHHD Review Panel Member Best Pharmaceuticals for Children Act Data Coordinating Center	2009
MN Partnership for Biotechnology and Medical Genomics Review Panel Member Scientific review of grant proposals	2009
NIDA Review Panel Member Data and Statistics Center for NIDA Clinical Trials Network	2009
Thoracic Cancer Committee Lead Statistician American College of Surgeons Oncology Group	2009 to 2011
Reviewer British Journal of Cancer	2009 to present
Reviewer Clinical Trials	2009 to present
Reviewer Plos1	2009 to present
NCI Review Panel Member Clinical Proteomic Technologies for Cancer Initiative: Proteome Characterization Centers	2010
NICHHD Review Panel Member Pediatric Trials Network	2010
Review Panel Member National Cancer Institute of Canada	2010
DOD CDMRP Review Panel Member	2010-2019
Data Monitoring Committee Chair University of Minnesota Iron Study	2010 to 2014
Data Monitoring Committee Member Eli Lilly 14T-MC-JVBB Trial	2010 to 2014
Data Monitoring Committee Incyte RESPONSE Trial	2010 to 2014
Associate Editor Journal of Clinical Oncology	2010 to 2017
Deputy Editor Journal of Clinical Oncology	2017-present
Reviewer Nature	2010, 2013, 2017, 2018
NICHHD Review Panel Member Systematic Review of Neonatal Medicine	2011
NICHHD Review Panel Member Maintenance of Child Health and Development Studies Name and Address Files	2011
Dutch Cancer Society Review Panel Member Scientific Grant Review	2011, 2014, 2015
Reviewer Annals of Surgery	2011 to present
Operations Committee Member Alliance Adult Cancer Cooperative Group	2011 to 2015
Scientific Concept Peer Review Committee Member Alliance Adult Cancer Cooperative Group	2011 to 2014
Data Safety Monitoring Board Chair Kanas University PAD in AA Trial	2011 to 2018
NICHHD Review Panel Member Folic Acid Supplementation and Semen Quality Trial (FAAST)	2012
NIAID Review Panel Member Pre-Clinical Pharmacology and Toxicology Studies	2012
NCI Review Panel Pre-clinical Efficacy and Intermediate Endpoint	2012

NIDA Review Panel Data, Statistics, and Clinical Trial Support for NIDA	2012, 2014
Cancer in the Elderly Committee Lead Statistician Alliance Adult Cancer Cooperative Group	2012 to 2015
NICHHD Review Panel Member Multiple Study Data Coordinating Center for DESPR	2013
Mayo Clinic Review Panel Member Microbiome Program Clinic Trial Funding	2013
NICHHD Review Panel Member Further Investigation into the Causes of Stillbirth Concept Clearance	2013
Publications Committee Member Alliance Adult Cancer Cooperative Group	2013 to 2016
Neuro-Oncology Committee Lead Statistician Alliance Adult Cancer Cooperative Group	2013 to present
FDA Medical Devices Advisory Committee Member General and Plastic Surgery Devices	2013 to present
Damon Runyon Foundation Review Panel Member Clinical Investigator Award	2013 to present
NCI Brain Malignancies Steering Committee member	2013 to present
NCI Review Panel Member PLCO Secondary Studies Proposals	2014, 2015
NIAID Review Panel Member Inner City Asthma Consortium (ICAC3)	2014
Associate Editor Neuro-Oncology	2014 to 2018
Data Safety and Monitoring Board Committee Member NIDDK	2014 to present
NICHHD Review Panel Member P01 Pre-Natal Microbiome Grant Review	2015
NIAID Review Panel Member Centers for Medical Countermeasures against Radiation Consortium (U19)	2015
Cancer Research UK Review Panel Member Biomarker Project Award	2015
Statistical Associate Editor American Journal of Respiratory and Critical Care Medicine	2015 to present
Independent Data Monitoring Committee Member Ariad Phase II trial of AP26113 in non-small cell lung cancer	2015-2018
NIAMS Technical Evaluation Panel Member Clinical Studies Management and Support	2016
NIAID Scientific Review Panel Member Asthma and Allergic Diseases Cooperative Research Centers	2016
NICHD Technical Evaluation Panel Member Best Pharmaceutical for Children Act Data Coordinating Center	2016
NINDS Scientific Review Panel Member Parkinson's Disease Biomarkers Program	2016
Cancer Research United Kingdom Review Panel Member Program Project Submission	2016
Data Safety and Monitoring Board Member The Comparison of Outcomes of Antibiotic Drugs and Appendectomy (CODA) Trial	2016 to present
United States Army Medical Research and Materiel Command (MRMC) Peer Review Panel Member	2016-2018
KNOD Study Section Committee Member	2018 to present
Cancer Moonshot Initiative: Human Tumor Atlas Research Centers (U2C) review panel member	2018
Clinical Research Training Institute Summer Workshop Faculty Member American Society of Hematology	2016 to present
Cancer LinQ Publications Committee Member	2016 to present
STATS.org Statistical Advisory Board Member	2016 to present

NIH/NIAID Asthma and Allergic Diseases Cooperative Research Centers	2017
NCI Program Project Grant (P01) Review Committee Member	2017
Data Safety and Monitoring Board Member Clofazimine in the treatment of pulmonary Mycobacterium avium complex (MAC) disease trial	2017 to present
NCI Oncology E Review Panel Member	2017
ASCO CancerLinQ Research and Publications Committee Member	2017 to present
Conquer Cancer Foundation Grant Selection Committee Member	2017 to present
Independent Data Monitoring Committee Member Takeda Phase III trial of brigatinib in non-small cell lung cancer	2018 to present
NCI Moonshot Initiative, the NCI Human Tumor Atlas Network (HTAN) Review Committee Member	2018
NCI Breast Cancer Steering Committee Member	2018 to present
NCI Program Project Grant (P01) Review V Committee Member	2019

#### J. PROFESSIONAL MEMBERSHIPS

Include medical and scientific societies

Member/Officer/Fellow/Role	Organization	Dates
Member	Operations Research Society of America	1990 to 1993
Officer	Operations Research Society of America	1992
Member	Mathematical Association of America	1991 to 1997
Officer	American Statistical Association	2000 to 2003; 2011 to 2013
Member	American Statistical Association	2000 to present
Member	American Society of Clinical Oncology	2005 to present
Member	Society of Neuro-Oncology	2007-present
Member	International Biometric Society, East North American Region	2006 to present
Officer	International Biometric Society, East North American Region	2008 to 2011
Member	Society of Clinical Trials	2008 to present

#### K. HONORS AND AWARDS

Name of award	Date awarded
Pi Mu Epsilon (Math honorary) - Macalester College	1980
Phi Beta Kappa - Macalester College	1982
Magna Cum Laude - Macalester College	1983
Academic All-American, Division III Volleyball - Macalester College	1983
Fredrick Hennie II Teaching Award - Massachusetts Institute of Technology	1987
Health Sciences Research Distinguished Teaching Award - Mayo Clinic	2004
Macalester College Distinguished Alumni in Science	2015

#### L. BIBLIOGRAPHY

##### 1. Articles in professional peer-reviewed journals

1. **Ballman KV.** Greater emphasis on variation in an introductory statistics course. J Statistics Education. 1997; 5(2).
2. Singh M, Nuttall GA, **Ballman KV**, Mullany CJ, Berger PB, Holmes DR Jr, Bell MR. Effect of abciximab on the outcome of emergency coronary artery bypass grafting after failed percutaneous coronary intervention. Mayo Clin Proc. 2001 Aug; 76(8):784-8. PMID:11499816. DOI:10.1016/S0025-6196(11)63221-7.

3. McConnell JP, Branum EL, **Ballman KV**, Lagerstedt SA, Katzmann JA, Jaffe AS. Gender differences in C-reactive protein concentrations - Confirmation with two sensitive methods. *Clinical Chemistry & Laboratory Medicine*. 2002; 40(1):56-9. PMID:11916271.
4. Aviles RJ, Wright RS, Aviles JM, McDonald F, **Ballman K**, Harker-Murray A, Scott C, Lauer MS, Kopecky SL, Jaffe AS. Long-term prognosis of patients with clinical unstable angina pectoris without elevation of creatine kinase but with elevation of cardiac troponin I levels. *Am J Cardiol*. 2002 Oct 15; 90(8):875-8. PMID:12372578.
5. Brilakis ES, McConnell JP, **Ballman KV**, Klee GG, Berger PB. Lack of association between plasma homocysteine and angiographic coronary artery disease in the era of fortification of cereal grain flour with folic acid. *Atherosclerosis*. 2002 Dec; 165(2):375-81. PMID:12417290.
6. Squires RW, Leung TC, Cyr NS, Allison TG, Johnson BD, **Ballman KV**, Wagner JA, Olson LJ, Frantz RP, Edwards BS, Kushwaha SS, Dearani JA, Daly RC, McGregor CG, Rodeheffer RJ. Partial normalization of the heart rate response to exercise after cardiac transplantation: frequency and relationship to exercise capacity. *Mayo Clin Proc*. 2002 Dec; 77(12):1295-300. PMID:12479515. DOI:10.4065/77.12.1295.
7. Leung TC, **Ballman KV**, Allison TG, Wagner JA, Olson LJ, Frantz RP, Edwards BS, Dearani JA, Daly RC, McGregor CG, Rodeheffer RJ. Clinical predictors of exercise capacity 1 year after cardiac transplantation. *J Heart Lung Transplant*. 2003 Jan; 22(1):16-27. PMID:12531409.
8. Weisberg IS, Park E, **Ballman KV**, Berger P, Nunn M, Suh DS, Breksa AP, Garrow TA, Rozen R. Investigations of a common genetic methyltransferase (BHMT) variant in betaine-homocysteine in coronary artery disease. *Atherosclerosis*. 2003 Apr; 167(2):205-14. PMID:12818402.
9. O'Neill BP, Iturria NJ, Link MJ, Pollock BE, **Ballman KV**, O'Fallon JR. A comparison of surgical resection and stereotactic radiosurgery in the treatment of solitary brain metastases. *Int J Radiat Oncol Biol Phys*. 2003 Apr 1; 55(5):1169-76. PMID:12654423.
10. Takemoto Y, Tanabe K, Chandrasekaran KW, **Ballman KV**, Seward JB, Belohlavek M. Single-plane and biplane echocardiography: Use of targeted scan planes improves the estimates of left ventricular volume and shape for analysis of postinfarction remodeling. *J Am Soc Echocardiogr*. 2003 May; 16(5):448-56. PMID:12724654.
11. Barretto S, **Ballman KV**, Rooke TW, Kullo IJ. Early-onset peripheral arterial occlusive disease: clinical features and determinants of disease severity and location. *Vasc Med*. 2003 May; 8(2):95-100. PMID:14518611.
12. Gami AS, Wright RS, **Ballman KV**, Kopecky SL, Hayes SN. Hormone replacement therapy and risk of acute myocardial infarction in postmenopausal women with diabetes mellitus. *Am J Cardiol*. 2003 May 15; 91(10):1275-7. PMID:12745121.
13. Kanagala R, Murali NS, Friedman PA, Ammash NM, Gersh BJ, **Ballman KV**, Shamsuzzaman ASM, Somers VK. Obstructive sleep apnea and the recurrence of atrial fibrillation. *Circulation*. 2003 May 27; 107(20):2589-94. PMID:12743002.
14. Brilakis ES, Berger PB, **Ballman KV**, Rozen R. Methylenetetrahydrofolate reductase (MTHFR) 677C>T and methionine synthase reductase (MTRR) 66A>G polymorphisms: association with serum homocysteine and angiographic coronary artery disease in the era of flour products fortified with folic acid. *Atherosclerosis*. 2003 Jun; 168(2):315-22. PMID:12801615.
15. Michels VV, Olson TM, Miller FA, **Ballman KV**, Rosales AG, Driscoll DJ. Frequency of development of idiopathic dilated cardiomyopathy among relatives of patients with idiopathic dilated cardiomyopathy. *Am J Cardiol*. 2003 Jun 1; 91(11):1389-92. PMID:12767445.
16. Bunch TJ, White RD, Gersh BJ, Meverden RA, Hodge DO, **Ballman KV**, Hammill SC, Shen WK, Packer DL. Long-term outcomes of out-of-hospital cardiac arrest after successful early defibrillation. *N Engl J Med*. 2003 Jun 26; 348(26):2626-33. PMID:12826637. DOI:10.1056/NEJMoa023053.
17. Gurevitz OT, Friedman PA, Glikson M, Trusty JM, **Ballman KV**, Rosales AG, Hayes DL, Hammill SC, Swerdlow CD. Discrepancies between the upper limit of vulnerability and defibrillation threshold: Prevalence and clinical predictors. *J Cardiovasc Electrophysiol*. 2003 Jul; 14(7):728-32. PMID:12930253.

18. Strome SE, Dong H, Tamura H, Voss SG, Flies DB, Tamada K, Salomao D, Chevillie J, Hirano F, Lin W, Kasperbauer JL, **Ballman KV**, Chen L. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. *Cancer Res.* 2003 Oct 1; 63(19):6501-5. PMID:14559843.
19. Spotila LD, Jacques PF, Berger PB, **Ballman KV**, Ellison RC, Rozen R. Age dependence of the influence of methylenetetrahydrofolate reductase genotype on plasma homocysteine level. *Am J Epidemiol.* 2003 Nov 1; 158(9):871-7. PMID:14585765.
20. Aldape KD, **Ballman KV**, Furth A, Buckner JC, Giannini C, Burger PC, Scheithauer BW, Jenkins RB, James CD. Immunohistochemical detection of EGFRvIII in malignant astrocytomas and evaluation of prognostic significance. *Journal of Neuropathology and Experimental Neurology.* 2004; 63(7):700-707.
21. Gurevitz O, Viskin S, Glikson M, **Ballman KV**, Rosales AG, Shen WK, Hammill SC, Friedman PA. Long-term prognosis of inducible ventricular flutter: not an innocent finding. *Am Heart J.* 2004 Apr; 147(4):649-54. PMID:15077080.
22. Glikson M, Lipchenca I, Viskin S, **Ballman KV**, Trusty JM, Gurevitz OT, Luria DM, Eldar M, Hammill SC, Friedman PA. Long-term outcome of patients who received implantable cardioverter defibrillators for stable ventricular tachycardia. *J Cardiovasc Electrophysiol.* 2004 Jun; 15(6):658-64. PMID:15175060.
23. Aldape KD, **Ballman K**, Furth A, Buckner JC, Giannini C, Burger PC, Scheithauer BW, Jenkins RB, James CD. Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance. *J Neuropathol Exp Neurol.* 2004 Jul; 63(7):700-7. PMID:15290895.
24. Kernis SJ, Nkomo VT, Messika-Zeitoun D, Gersh BJ, Sundt TM, **Ballman KV**, Scott CG, Schaff HV, Enriquez-Sarano M. Atrial fibrillation after surgical correction of mitral regurgitation in sinus rhythm - Incidence, outcome, and determinants. *Circulation.* 2004 Oct 19; 110(16):2320-5. PMID:15477410.
25. Kremers HM, Nicola PJ, Crowson CS, **Ballman KV**, Gabriel SE. Prognostic importance of low body mass index in relation to cardiovascular mortality in rheumatoid arthritis. *Arthritis Rheum.* 2004 Nov; 50(11):3450-7. PMID:15529378.
26. **Ballman KV**, Grill DE, Oberg AL, Therneau TM. Faster cyclic loess: normalizing RNA arrays via linear models. *Bioinformatics.* 2004 Nov 1; 20(16):2778-86. PMID:15166021.
27. Brown PD, Petersen IA, Schomberg PJ, Ivnik RJ, Furth AF, **Ballman KV**, Hammack JE, Buckner JC, Shaw EG, Arusell R. Cognitive function after radiotherapy for supratentorial low-grade glioma: a North Central Cancer Treatment Group prospective study. *Int J Radiat Oncol Biol Phys.* 2005; 58(4):1153-60.
28. Brown P, **Ballman K**, Rummans T, Maurer M, Sloan J, Boeve B, Gupta L, Tang-Wai D, Arusell R, Clark M, Buckner J. Prospective study of quality of life in adults with newly diagnosed high-grade glioma: A North Central Cancer Treatment Group trial. *J Neuro-Oncol.* 2005; 57(3):495-504.
29. Kitange G, Misra A, Law M, Passe S, Kollmeyer TM, Maurer M, **Ballman K**, Feuerstein BG, Jenkins RB. Chromosomal imbalances detected by array comparative genomic hybridization in human oligodendrogliomas and mixed oligoastrocytomas. *Genes Chromosomes Cancer.* 2005 Jan; 42(1):68-77.
30. Abraham RS, **Ballman KV**, Dispenzieri A, Grill DE, Manske MK, Price-Troska TL, Paz NG, Gertz MA, Fonseca R. Functional gene expression analysis of clonal plasma cells identifies a unique molecular profile for light chain amyloidosis. *Blood.* 2005 Jan 15; 105(2):794-803. PMID:15388584.
31. Gurevitz OT, Ammash NM, Malouf JF, Chandrasekaran K, Rosales AG, **Ballman KV**, Hammill SC, White RD, Gersh BJ, Friedman PA. Comparative efficacy of monophasic and biphasic waveforms for transthoracic cardioversion of atrial fibrillation and atrial flutter. *Am Heart J.* 2005 Feb; 149(2):316-21. PMID:15846271. DOI:10.1016/j.ahj.2004.07.007.
32. Maradit-Kremers H, Crowson CS, Nicola PJ, **Ballman KV**, Roger VL, Jacobsen SJ, Gabriel SE. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis-a population-based cohort study. *Arthritis Rheum.* 2005 Feb; 52(2):402-11. PMID:15693010.
33. Nicola PJ, Maradit-Kremers H, Roger VL, Jacobsen SJ, Crowson CS, **Ballman KV**, Gabriel SE. The risk of congestive heart failure in rheumatoid arthritis-a population-based study over 46 years. *Arthritis Rheum.* 2005 Feb; 52(2):412-20. PMID:15692992.

34. Maradit-Kremers H, Nicola PJ, Crowson CS, **Ballman KV**, Gabriel SE. Cardiovascular death in rheumatoid arthritis: a population-based study. *Arthritis Rheum.* 2005 Mar; 52(3):722-32. PMID:15751097.
35. Yang P, Kollmeyer TM, Buckner K, Bamlet W, **Ballman KV**, Jenkins RB. Polymorphisms in GLTSCR1 and ERCC2 are associated with the development of oligodendrogliomas. *Cancer.* 2005 Jun 1; 103(11):2363-72. PMID:15834925. DOI:10.1002/cncr.21028.
36. Galanis E, Buckner JC, Maurer MJ, Kreisberg JI, **Ballman K**, Boni J, Peralba JM, Jenkins RB, Dakhil SR, Morton RF, Jaeckle KA, Scheithauer BW, Dancey J, Hidalgo M, Walsh DJ, North Central Cancer Treatment Group. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. *J Clin Oncol.* 2005 Aug 10; 23(23):5294-304. Epub 2005 Jul 05. PMID:15998902. DOI:10.1200/JCO.2005.23.622.
37. Brown PD, Maurer MJ, Rummans TA, Pollock BE, **Ballman KV**, Sloan JA, Boeve BF, Arusell RM, Clark MM, Buckner JC. A prospective study of quality of life in adults with newly diagnosed high-grade gliomas: the impact of the extent of resection on quality of life and survival. *Neurosurgery.* 2005 Sep; 57(3):495-504; discussion 495-504. PMID:16145528.
38. Crowson CS, Nicola PJ, Maradit Kremers H, O'Fallon WM, Therneau TM, Jacobsen SJ, Roger VL, **Ballman KV**, Gabriel SE. How much of the increased incidence of heart failure in rheumatoid arthritis is attributable to traditional cardiovascular risk factors and ischemic heart disease? *Arthritis Rheum.* 2005 Oct; 52(10):3039-44. PMID:16200583.
39. Laack NN, Brown PD, Ivnik RJ, Furth AF, **Ballman KV**, Hammack JE, Arusell RM, Shaw EG, Buckner JC. Cognitive function after radiotherapy for supratentorial low-grade glioma: A North Central Cancer Treatment Group prospective study. *Int J Radiat Oncol Biol Phys.* 2005 Nov 15; 63(4):1175-83.
40. Miller WL, **Ballman KV**, Hodge DO, Rodeheffer RJ, Hammill SC. Risk factor implications of incidentally discovered uncomplicated bundle branch block. *Mayo Clin Proc.* 2005 Dec; 80(12):1585-90. PMID:16342651. DOI:10.4065/80.12.1585.
41. Brown PD, Foote RL, McLaughlin MP, Halyard MY, **Ballman KV**, Collie AC, Miller RC, Flemming KD, Hallett JW. A historical prospective cohort study of carotid artery stenosis after radiotherapy for head and neck malignancies. *Int J Radiat Oncol Biol Phys.* 2005 Dec 1; 63(5):1361-7. Epub 2005 Sep 19. PMID:16169673. DOI:10.1016/j.ijrobp.2005.05.046.
42. Cooper LT, Henderson SS, **Ballman KV**, Offord KP, Tse TS, Holmes DR, Hurt RD. A prospective, case-control study of tobacco dependence in thromboangiitis obliterans (Buerger's Disease). *Angiology.* 2006 Jan-Feb; 57(1):73-8. PMID:16444459.
43. Nicola PJ, Crowson CS, Maradit-Kremers H, **Ballman KV**, Roger VL, Jacobsen SJ, Gabriel SE. Contribution of congestive heart failure and ischemic heart disease to excess mortality in rheumatoid arthritis. *Arthritis Rheum.* 2006 Jan; 54(1):60-7. PMID:16385496. DOI:10.1002/art.21560.
44. Brown PD, **Ballman KV**, Rummans TA, Maurer MJ, Sloan JA, Boeve BF, Gupta L, Tang-Wai DF, Arusell RM, Clark MM, Buckner JC. Prospective study of quality of life in adults with newly diagnosed high-grade gliomas. *J Neurooncol.* 2006 Feb; 76(3):283-91. PMID:16163448. DOI:10.1007/s11060-005-7020-9.
45. Vanaja DK, **Ballman KV**, Morlan BW, Chevillie JC, Neumann RM, Lieber MM, Tindall DJ, Young CY. PDLIM4 repression by hypermethylation as a potential biomarker for prostate cancer. *Clin Cancer Res.* 2006 Feb 15; 12(4):1128-36. PMID:16489065. DOI:10.1158/1078-0432.CCR-05-2072.
46. Jaeckle KA, **Ballman KV**, Rao RD, Jenkins RB, Buckner JC. Current strategies in treatment of oligodendroglioma: evolution of molecular signatures of response. *J Clin Oncol.* 2006 Mar 10; 24(8):1246-52. PMID:16525179. DOI:10.1200/JCO.2005.04.9874.
47. Witt BJ, **Ballman KV**, Brown RD, Meverden RA, Jacobsen SJ, Roger VL. The incidence of stroke after myocardial infarction: a meta-analysis. *Am J Med.* 2006 Apr; 119(4):354.e1-9. PMID:16564779. DOI:10.1016/j.amjmed.2005.10.058.
48. Galanis E, Buckner JC, Maurer MJ, Sykora R, Castillo R, **Ballman KV**, Erickson BJ. Validation of neuroradiologic response assessment in gliomas: measurement by RECIST, two-dimensional, computer-assisted tumor area, and computer-assisted tumor volume methods. *Neuro Oncol.* 2006 Apr; 8(2):156-65. Epub 2006 Mar 02. PMID:16533757. PMCID:1871930. DOI:10.1215/15228517-2005-005.

49. Sarkaria JN, Carlson BL, Schroeder MA, Grogan P, Brown PD, Giannini C, **Ballman KV**, Kitange GJ, Guha A, Pandita A, James CD. Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response. *Clin Cancer Res*. 2006 Apr 1; 12(7 Pt 1):2264-71. PMID:16609043. DOI:10.1158/1078-0432.CCR-05-2510.
50. Marshall NE, **Ballman KV**, Michalak JC, Schomberg PJ, Burton GV, Sandler HM, Cascino TL, Jaeckle KA, Buckner JC. Ototoxicity of cisplatin plus standard radiation therapy vs. accelerated radiation therapy in glioblastoma patients. *J Neurooncol*. 2006 May; 77(3):315-20. PMID:16273313. DOI:10.1007/s11060-005-9049-1.
51. Witt BJ, Brown RD, Jacobsen SJ, Weston SA, **Ballman KV**, Meverden RA, Roger VL. Ischemic stroke after heart failure: a community-based study. *Am Heart J*. 2006 Jul; 152(1):102-9. PMID:16824838. DOI:10.1016/j.ahj.2005.10.018.
52. Murillo H, Schmidt LJ, Karter M, Hafner KA, Kondo Y, **Ballman KV**, Vasmatazis G, Jenkins RB, Tindall DJ. Prostate cancer cells use genetic and epigenetic mechanisms for progression to androgen independence. *Genes Chromosomes Cancer*. 2006 Jul; 45(7):702-16. PMID:16615098. DOI:10.1002/gcc.20333.
53. Krishnan S, Brown PD, **Ballman KV**, Fiveash JB, Uhm JH, Giannini C, Jaeckle KA, Geoffroy FJ, Nabors LB, Buckner JC, North Central Cancer Treatment Group. Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177. *Int J Radiat Oncol Biol Phys*. 2006 Jul 15; 65(4):1192-9. Epub 2006 Apr 19. PMID:16626884. DOI:10.1016/j.ijrobp.2006.01.018.
54. Laack NN, **Ballman KV**, Brown PB, O'Neill BP, North Central Cancer Treatment Group. Whole-brain radiotherapy and high-dose methylprednisolone for elderly patients with primary central nervous system lymphoma: Results of North Central Cancer Treatment Group (NCCTG) 96-73-51. *Int J Radiat Oncol Biol Phys*. 2006 Aug 1; 65(5):1429-39. PMID:16863926. DOI:10.1016/j.ijrobp.2006.03.061.
55. Buckner JC, **Ballman KV**, Michalak JC, Burton GV, Cascino TL, Schomberg PJ, Hawkins RB, Scheithauer BW, Sandler HM, Marks RS, O'Fallon JR, North Central Cancer Treatment Group 93-72-52, Southwest Oncology Group 9503 Trials. Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group 9503 Trials. *J Clin Oncol*. 2006 Aug 20; 24(24):3871-9. PMID:16921039. DOI:10.1200/JCO.2005.04.6979.
56. Oberg AL, Mahoney DW, **Ballman KV**, Therneau TM. Joint estimation of calibration and expression for high-density oligonucleotide arrays. *Bioinformatics*. 2006 Oct 1; 22(19):2381-7. Epub 2006 Jul 28. PMID:16877757. DOI:10.1093/bioinformatics/btl399.
57. Jenkins RB, Blair H, **Ballman KV**, Giannini C, Arusell RM, Law M, Flynn H, Passe S, Felten S, Brown PD, Shaw EG, Buckner JC. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. *Cancer Res*. 2006 Oct 15; 66(20):9852-61. PMID:17047046. DOI:10.1158/0008-5472.CAN-06-1796.
58. Babovic-Vuksanovic D, **Ballman K**, Michels V, McGrann P, Lindor N, King B, Camp J, Micic V, Babovic N, Carrero X, Spinner R, O'Neill B. Phase II trial of pirfenidone in adults with neurofibromatosis type 1. *Neurology*. 2006 Nov 28; 67(10):1860-2. Epub 2006 Oct 11. PMID:17035676. DOI:10.1212/01.wnl.0000243231.12248.67.
59. Brown PD, Jensen AW, Felten SJ, **Ballman KV**, Schaefer PL, Jaeckle KA, Cerhan JH, Buckner JC. Detrimental effects of tumor progression on cognitive function of patients with high-grade glioma. *J Clin Oncol*. 2006 Dec 1; 24(34):5427-33. PMID:17135644. DOI:10.1200/JCO.2006.08.5605.
60. Maradit-Kremers H, Nicola PJ, Crowson CS, **Ballman KV**, Jacobsen SJ, Roger VL, Gabriel SE. Raised erythrocyte sedimentation rate signals heart failure in patients with rheumatoid arthritis. *Ann Rheum Dis*. 2007 Jan; 66(1):76-80. Epub 2006 Jul 03. PMID:16818462. PMCID:1798392. DOI:10.1136/ard.2006.053710.
61. Mercader M, Sengupta S, Bodner BK, Manecke RG, Cosar EF, Moser MT, **Ballman KV**, Wojcik EM, Kwon ED. Early effects of pharmacological androgen deprivation in human prostate cancer. *BJU Int*. 2007 Jan; 99(1):60-7. PMID:17227493. DOI:10.1111/j.1464-410X.2007.06538.x.

62. **Ballman KV**, Buckner JC, Brown PD, Giannini C, Flynn PJ, LaPlant BR, Jaeckle KA. The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. *Neuro Oncol.* 2007 Jan; 9(1):29-38. Epub 2006 Nov 15 PMID:17108063. PMCID:1828103. DOI:10.1215/15228517-2006-025.
63. Davis JM 3rd, Maradit Kremers H, Crowson CS, Nicola PJ, **Ballman KV**, Therneau TM, Roger VL, Gabriel SE. Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study. *Arthritis Rheum.* 2007 Mar; 56(3):820-30. PMID:17330254.
64. Meyers BF, Downey RJ, Decker PA, Keenan RJ, Siegel BA, Cerfolio RJ, Landreneau RJ, Reed CE, Balfe DM, Dehdashti F, **Ballman KV**, Rusch VW, Putnam JB Jr, American College of Surgeons Oncology Group Z0060. The utility of positron emission tomography in staging of potentially operable carcinoma of the thoracic esophagus: results of the American College of Surgeons Oncology Group Z0060 trial. *J Thorac Cardiovasc Surg.* 2007 Mar; 133(3):738-45. PMID:17320575.
65. Majumdar R, Miller DV, **Ballman KV**, Unnikrishnan G, McKellar SH, Sarkar G, Sreekumar R, Bolander ME, Sundt TM 3rd. Elevated expressions of osteopontin and tenascin C in ascending aortic aneurysms are associated with trileaflet aortic valves as compared with bicuspid aortic valves. *Cardiovasc Pathol.* 2007 May-Jun; 16(3):144-50. Epub 2007 Feb 21. PMID:17502243. DOI:10.1016/j.carpath.2006.12.001.
66. Pelloski CE, **Ballman KV**, Furth AF, Zhang L, Lin E, Sulman EP, Bhat K, McDonald JM, Yung WK, Colman H, Woo SY, Heimberger AB, Suki D, Prados MD, Chang SM, Barker FG, Buckner JC, James CD, Aldape K. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. *J Clin Oncol.* 2007 Jun 1; 25(16):2288-94. PMID:17538175. DOI:10.1200/JCO.2006.08.0705.
67. Schmidt LJ, **Ballman KV**, Tindall DJ. Inhibition of fatty acid synthase activity in prostate cancer cells by dutasteride. *Prostate.* 2007 Jul 1; 67(10):1111-20. PMID:17477363. DOI:10.1002/pros.20602.
68. Witt BJ, Gami AS, **Ballman KV**, Brown RD Jr, Meverden RA, Jacobsen SJ, Roger VL. The incidence of ischemic stroke in chronic heart failure: a meta-analysis. *J Card Fail.* 2007 Aug; 13(6):489-96. PMID:17675064. DOI:10.1016/j.cardfail.2007.01.009.
69. Buckner JC, O'Fallon JR, Dinapoli RP, Schomberg PJ, Farr G, Schaefer P, Giannini C, Scheithauer BW, **Ballman KV**. Prognosis in patients with anaplastic oligoastrocytoma is associated with histologic grade. *J Neurooncol.* 2007 Sep; 84(3):279-86. Epub 2007 Apr 13. PMID:17431544. DOI:10.1007/s11060-007-9370-y.
70. Locke DE, Decker PA, Sloan JA, Brown PD, Malec JF, Clark MM, Rummans TA, **Ballman KV**, Schaefer PL, Buckner JC. Validation of single-item linear analog scale assessment of quality of life in neuro-oncology patients. *J Pain Symptom Manage.* 2007 Dec; 34(6):628-38. Epub 2007 Aug 20. PMID:17703910. PMCID:2732111. DOI:10.1016/j.jpainsymman.2007.01.016.
71. Therneau TM, **Ballman KV**. What does PLIER really do? *Cancer Inform.* 2008; 6:423-31. Epub 2008 Aug 27. PMID:19259420. PMCID:2623311.
72. Nakagawa T, Kollmeyer TM, Morlan BW, Anderson SK, Bergstralh EJ, Davis BJ, Asmann YW, Klee GG, **Ballman KV**, Jenkins RB. A tissue biomarker panel predicting systemic progression after PSA recurrence post-definitive prostate cancer therapy. *PLoS One.* 2008; 3(5):e2318. Epub 2008 May 28. PMID:18846227. PMCID:2565588. DOI:10.1371/journal.pone.0002318.
73. Gonzalez A, Maradit Kremers H, Crowson CS, **Ballman KV**, Roger VL, Jacobsen SJ, O'Fallon WM, Gabriel SE. Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients? *Ann Rheum Dis.* 2008 Jan; 67(1):64-9. Epub 2007 May 21. PMID:17517756. DOI:10.1136/ard.2006.059980.
74. Brown PD, Decker PA, Rummans TA, Clark MM, Frost MH, **Ballman KV**, Arusell RM, Buckner JC. A prospective study of quality of life in adults with newly diagnosed high-grade gliomas: comparison of patient and caregiver ratings of quality of life. *Am J Clin Oncol.* 2008 Apr; 31(2):163-8. PMID:18391601. DOI:10.1097/COC.0b013e318149f1d3.
75. McCollum AK, TenEyck CJ, Stensgard B, Morlan BW, **Ballman KV**, Jenkins RB, Toft DO, Erlichman C. P-Glycoprotein-mediated resistance to Hsp90-directed therapy is eclipsed by the heat shock response. *Cancer Res.* 2008 Sep 15; 68(18):7419-27. PMID:18794130. PMCID:2695926. DOI:10.1158/0008-5472.CAN-07-5175.

76. **Ballman KV.** Genetics and genomics: gene expression microarrays. *Circulation*. 2008 Oct 7; 118(15):1593-7. PMID:18838575. DOI:10.1161/CIRCULATIONAHA.107.714600.
77. Cooper LT Jr, Hare JM, Tazelaar HD, Edwards WD, Starling RC, Deng MC, Menon S, Mullen GM, Jaski B, Bailey KR, Cunningham MW, Dec GW, **Giant Cell Myocarditis Treatment Trial Investigators.** Usefulness of immunosuppression for giant cell myocarditis. *Am J Cardiol*. 2008 Dec 1; 102(11):1535-9. Epub 2008 Sep 18. PMID:19026310. PMCID:2613862. DOI:10.1016/j.amjcard.2008.07.041.
78. Kitange GJ, Carlson BL, Mladek AC, Decker PA, Schroeder MA, Wu W, Grogan PT, Giannini C, **Ballman KV,** Buckner JC, James CD, Sarkaria JN. Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model. *J Neurooncol*. 2009 Mar; 92(1):23-31. Epub 2008 Nov 15. PMID:19011762. PMCID:2790867. DOI:10.1007/s11060-008-9737-8.
79. Dematteo RP, **Ballman KV,** Antonescu CR, Maki RG, Pisters PW, Demetri GD, Blackstein ME, Blanke CD, von Mehren M, Brennan MF, Patel S, McCarter MD, Polikoff JA, Tan BR, Owzar K, American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. *Lancet*. 2009 Mar 28; 373(9669):1097-104. Epub 2009 Mar 18. PMID:19303137. PMCID:2915459. DOI:10.1016/S0140-6736(09)60500-6.
80. Heemers HV, Regan KM, Schmidt LJ, Anderson SK, **Ballman KV,** Tindall DJ. Androgen modulation of coregulator expression in prostate cancer cells. *Mol Endocrinol*. 2009 Apr; 23(4):572-83. Epub 2009 Jan 22. PMID:19164447. PMCID:2667711. DOI:10.1210/me.2008-0363.
81. Wrensch M, Jenkins RB, Chang JS, Yeh RF, Xiao Y, Decker PA, **Ballman KV,** Berger M, Buckner JC, Chang S, Giannini C, Halder C, Kollmeyer TM, Kosel ML, LaChance DH, McCoy L, O'Neill BP, Patoka J, Pico AR, Prados M, Quesenberry C, Rice T, Rynearson AL, Smirnov I, Tihan T, Wiemels J, Yang P, Wiencke JK. Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. *Nat Genet*. 2009 Aug; 41(8):905-8. Epub 2009 Jul 05. PMID:19578366. PMCID:2923561. DOI:10.1038/ng.408.
82. Carlson BL, Grogan PT, Mladek AC, Schroeder MA, Kitange GJ, Decker PA, Giannini C, Wu W, **Ballman KA,** James CD, Sarkaria JN. Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts. *Int J Radiat Oncol Biol Phys*. 2009 Sep 1; 75(1):212-9. PMID:19695438. PMCID:2773462. DOI:10.1016/j.ijrobp.2009.04.026.
83. Drucker KL, Kitange GJ, Kollmeyer TM, Law ME, Passe S, Rynearson AL, Blair H, Soderberg CL, Morlan BW, **Ballman KV,** Giannini C, Jenkins RB. Characterization and gene expression profiling in glioma cell lines with deletion of chromosome 19 before and after microcell-mediated restoration of normal human chromosome 19. *Genes Chromosomes Cancer*. 2009 Oct; 48(10):854-64. PMID:19544381. PMCID:3190979. DOI:10.1002/gcc.20688.
84. Jaekle KA, **Ballman K,** Furth A, Buckner JC. Correlation of enzyme-inducing anticonvulsant use with outcome of patients with glioblastoma. *Neurology*. 2009 Oct 13; 73(15):1207-13. PMID:19822870. PMCID:2764724. DOI:10.1212/WNL.0b013e3181bbfeca.
85. Schmidt LJ, Regan KM, Anderson SK, Sun Z, **Ballman KV,** Tindall DJ. Effects of the 5 alpha-reductase inhibitor dutasteride on gene expression in prostate cancer xenografts. *Prostate*. 2009 Dec 1; 69(16):1730-43. PMID:19676081. PMCID:2783419. DOI:10.1002/pros.21022.
86. Hillman SL, Mandrekar SJ, Bot B, DeMatteo RP, Perez EA, **Ballman KV,** Nelson H, Buckner JC, Sargent DJ. Evaluation of the value of attribution in the interpretation of adverse event data: a North Central Cancer Treatment Group and American College of Surgeons Oncology Group investigation. *J Clin Oncol*. 2010 Jun 20; 28(18):3002-7. Epub 2010 May 17. PMID:20479400. PMCID:2903334. DOI:10.1200/JCO.2009.27.4282.
87. Wilke LG, **Ballman KV,** McCall LM, Giuliano AE, Whitworth PW, Blumencranz PW, Reintgen DS, Burak WE, Leitch AM, Hunt KK. Adherence to the National Quality Forum (NQF) breast cancer measures within cancer clinical trials: a review from ACOSOG Z0010. *Ann Surg Oncol*. 2010 Aug; 17(8):1989-94. Epub 2010 Mar 23. PMID:20309640. PMCID:2950006. DOI:10.1245/s10434-010-0980-9.

88. Jaeckle KA, **Ballman KV**, Giannini C, Schomberg PJ, Ames MM, Reid JM, McGovern RM, Safgren SL, Galanis E, Uhm JH, Brown PD, Hammack JE, Arusell R, Nikcevich DA, Morton RF, Wender DB, Buckner JC. Phase II NCCTG trial of RT + irinotecan and adjuvant BCNU plus irinotecan for newly diagnosed GBM. *J Neurooncol.* 2010 Aug; 99(1):73-80. Epub 2010 Jan 09. PMID:20063115. PMCID:2897141. DOI:10.1007/s11060-009-0103-2.
89. Giuliano AE, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM, Saha S, Hunt KK, Morrow M, **Ballman K**. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. *Ann Surg.* 2010 Sep; 252(3):426-32; discussion 432-3. PMID:20739842. DOI:10.1097/SLA.0b013e3181f08f32.
90. Kitange GJ, Carlson BL, Schroeder MA, Decker PA, Morlan BW, Wu W, **Ballman KV**, Giannini C, Sarkaria JN. Expression of CD74 in high grade gliomas: a potential role in temozolomide resistance. *J Neurooncol.* 2010 Nov; 100(2):177-86. Epub 2010 May 05. PMID:20443131. PMCID:3233976. DOI:10.1007/s11060-010-0186-9.
91. Shi Q, You YN, Nelson H, Allen MS, Winchester D, Stewart A, Young-Fadok T, Decker PA, Green EM, Holton SJ, **Ballman KV**. Cancer registries: a novel alternative to long-term clinical trial follow-up based on results of a comparative study. *Clin Trials.* 2010 Dec; 7(6):686-95. Epub 2010 Aug 20. PMID:20729254. DOI:10.1177/1740774510380953.
92. Giuliano AE, Hunt KK, **Ballman KV**, Beitsch PD, Whitworth PW, Blumencranz PW, Leitch AM, Saha S, McCall LM, Morrow M. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. *JAMA.* 2011 Feb 9; 305(6):569-75. PMID:21304082. DOI:10.1001/jama.2011.90.
93. Darling GE, Allen MS, Decker PA, **Ballman K**, Malthaner RA, Inculet RI, Jones DR, McKenna RJ, Landreneau RJ, Rusch VW, Putnam JB. Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: results of the American College of Surgery Oncology Group Z0030 Trial. *J Thorac Cardiovasc Surg.* 2011 Mar; 141(3):662-70. PMID:21335122. DOI:10.1016/j.jtcvs.2010.11.008.
94. Heemers HV, Schmidt LJ, Sun Z, Regan KM, Anderson SK, Duncan K, Wang D, Liu S, **Ballman KV**, Tindall DJ. Identification of a clinically relevant androgen-dependent gene signature in prostate cancer. *Cancer Res.* 2011 Mar 1; 71(5):1978-88. Epub 2011 Feb 15. PMID:21324924. PMCID:3077061. DOI:10.1158/0008-5472.CAN-10-2512.
95. Darling GE, Allen MS, Decker PA, **Ballman K**, Malthaner RA, Inculet RI, Jones DR, McKenna RJ, Landreneau RJ, Putnam JB. Number of lymph nodes harvested from a mediastinal lymphadenectomy: results of the randomized, prospective American College of Surgeons Oncology Group Z0030 trial. *Chest.* 2011 May; 139(5):1124-9. Epub 2010 Sep 09. PMID:20829340. PMCID:3087457. DOI:10.1378/chest.10-0859.
96. Uhm JH, **Ballman KV**, Wu W, Giannini C, Krauss JC, Buckner JC, James CD, Scheithauer BW, Behrens RJ, Flynn PJ, Schaefer PL, Dakhill SR, Jaeckle KA. Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074. *Int J Radiat Oncol Biol Phys.* 2011 Jun 1; 80(2):347-53. Epub 2010 May 25. PMID:20510539. DOI:10.1016/j.ijrobp.2010.01.070.
97. Giuliano AE, Hawes D, **Ballman KV**, Whitworth PW, Blumencranz PW, Reintgen DS, Morrow M, Leitch AM, Hunt KK, McCall LM, Abati A, Cote R. Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer. *JAMA.* 2011 Jul 27; 306(4):385-93. PMID:21791687. DOI:10.1001/jama.2011.1034.
98. Jaeckle KA, Decker PA, **Ballman KV**, Flynn PJ, Giannini C, Scheithauer BW, Jenkins RB, Buckner JC. Transformation of low grade glioma and correlation with outcome: an NCCTG database analysis. *J Neurooncol.* 2011 Aug; 104(1):253-9. Epub 2010 Dec 12. PMID:21153680. DOI:10.1007/s11060-010-0476-2.
99. Laack NN, O'Neill BP, **Ballman KV**, O'Fallon JR, Carrero XW, Kurtin PJ, Scheithauer BW, Brown PD, Habermann TM, Colgan JP, Gilbert MR, Hawkins RB, Morton RF, Windschitl HE, Fitch TR, Pajon ER Jr, North Central Cancer Treatment Group and Mayo Clinic. CHOD/BVAM chemotherapy and whole-brain radiotherapy for newly diagnosed primary central nervous system lymphoma. *Int J Radiat Oncol*

100. Rusch VW, Hawes D, Decker PA, Martin SE, Abati A, Landreneau RJ, Patterson GA, Inculet RI, Jones DR, Malthaner RA, Cohen RG, **Ballman K**, Putnam JB Jr, Cote RJ. Occult metastases in lymph nodes predict survival in resectable non-small-cell lung cancer: report of the ACOSOG Z0040 trial. *J Clin Oncol*. 2011 Nov 10; 29(32):4313-9. Epub 2011 Oct 11. PMID:21990404. PMCID:3221530. DOI:10.1200/JCO.2011.35.2500.
101. Toussaint LG III, Nilson AE, Goble JM, **Ballman KV**, James CD, Lefranc F, Kiss R, Uhm JH. Galectin-1, a gene preferentially expressed at the tumor margin, promotes glioblastoma cell invasion. *Mol Cancer*. 2012; 11:32. Epub 2012 May 14. PMID:22583806. PMCID:3407025. DOI:10.1186/1476-4598-11-32.
102. Deley MC, **Ballman KV**, Marandet J, Sargent D. Taking the long view: how to design a series of Phase III trials to maximize cumulative therapeutic benefit. *Clin Trials*. 2012 Jun; 9(3):283-92. Epub 2012 May 08. PMID:22569743. PMCID:3904223. DOI:10.1177/1740774512443430.
103. Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, Van Tine BA, Hoog J, Goiffon RJ, Goldstein TC, Ng S, Lin L, Crowder R, Snider J, **Ballman K**, Weber J, Chen K, Koboldt DC, Kandath C, Schierding WS, McMichael JF, Miller CA, Lu C, Harris CC, McLellan MD, Wendl MC, DeSchryver K, Allred DC, Esserman L, Unzeitig G, Margenthaler J, Babiera GV, Marcom PK, Guenther JM, Leitch M, Hunt K, Olson J, Tao Y, Maher CA, Fulton LL, Fulton RS, Harrison M, Oberkfell B, Du F, Demeter R, Vickery TL, Elhammali A, Piwnica-Worms H, McDonald S, Watson M, Dooling DJ, Ota D, Chang LW, Bose R, Ley TJ, Piwnica-Worms D, Stuart JM, Wilson RK, Mardis ER. Whole-genome analysis informs breast cancer response to aromatase inhibition. *Nature*. 2012 Jun 21; 486(7403):353-60. Epub 2012 Jun 10. PMID:22722193. PMCID:3383766. DOI:10.1038/nature11143.
104. McCarter MD, Antonescu CR, **Ballman KV**, Maki RG, Pisters PW, Demetri GD, Blanke CD, von Mehren M, Brennan MF, McCall L, Ota DM, DeMatteo RP, American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant Gist Study Team. Microscopically positive margins for primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrence. *J Am Coll Surg*. 2012 Jul; 215(1):53-9; discussion 59-60. PMID:22726733. PMCID:3383609. DOI:10.1016/j.jamcollsurg.2012.05.008.
105. Hunt KK, **Ballman KV**, McCall LM, Boughey JC, Mittendorf EA, Cox CE, Whitworth PW, Beitsch PD, Leitch AM, Buchholz TA, Morrow MA, Giuliano AE. Factors associated with local-regional recurrence after a negative sentinel node dissection: results of the ACOSOG Z0010 trial. *Ann Surg*. 2012 Sep; 256(3):428-36. PMID:22868365. DOI:10.1097/SLA.0b013e3182654494.
106. O'Brien KM, Orlow I, Antonescu CR, **Ballman K**, McCall L, DeMatteo R, Engel LS. Gastrointestinal stromal tumors, somatic mutations and candidate genetic risk variants. *PLoS One*. 2013; 8(4):e62119. Epub 2013 Apr 18. PMID:23637977. PMCID:3630216. DOI:10.1371/journal.pone.0062119.
107. Erho N, Crisan A, Vergara IA, Mitra AP, Ghadessi M, Buerki C, Bergstralh EJ, Kollmeyer T, Fink S, Haddad Z, Zimmermann B, Sierocinski T, **Ballman KV**, Triche TJ, Black PC, Karnes RJ, Klee G, Davicioni E, Jenkins RB. Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. *PLoS One*. 2013; 8(6):e66855. Epub 2013 Jun 24. PMID:23826159. PMCID:3691249. DOI:10.1371/journal.pone.0066855.
108. Garraway LA, Verweij J, **Ballman KV**. Precision oncology: an overview. *J Clin Oncol*. 2013 May 20; 31(15):1803-5. Epub 2013 Apr 15. PMID:23589545. DOI:10.1200/JCO.2013.49.4799.
109. Freedman RA, Pitcher B, Keating NL, **Ballman KV**, Mandelblatt J, Kornblith AB, Kimmick GG, Hurria A, Winer EP, Hudis CA, Cohen HJ, Muss HB, Alliance for Clinical Trials in Oncology. Cognitive function in older women with breast cancer treated with standard chemotherapy and capecitabine on Cancer and Leukemia Group B 49907. *Breast Cancer Res Treat*. 2013 Jun; 139(2):607-16. Epub 2013 May 17. PMID:23681403. PMCID:3920483. DOI:10.1007/s10549-013-2562-6.
110. Cen L, Carlson BL, Pokorny JL, Mladek AC, Grogan PT, Schroeder MA, Decker PA, Anderson SK, Giannini C, Wu W, **Ballman KV**, Kitange GJ, Sarkaria JN. Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models. *Neuro Oncol*. 2013 Jun; 15(6):735-46. Epub 2013 Mar 10. PMID:23479134. PMCID:3661094. DOI:10.1093/neuonc/not010.
111. Crozier JA, Moreno-Aspitia A, **Ballman KV**, Dueck AC, Pockaj BA, Perez EA. Effect of body mass index on tumor characteristics and disease-free survival in patients from the HER2-positive adjuvant

- trastuzumab trial N9831. *Cancer*. 2013 Jul 1; 119(13):2447-54. Epub 2013 Apr 12. PMID:23585192. PMCID:3686994. DOI:10.1002/cncr.28051.
112. Gami AS, Olson EJ, Shen WK, Wright RS, **Ballman KV**, Hodge DO, Herges RM, Howard DE, Somers VK. Obstructive sleep apnea and the risk of sudden cardiac death: a longitudinal study of 10,701 adults. *J Am Coll Cardiol*. 2013 Aug 13; 62(7):610-6. Epub 2013 Jun 13. PMID:23770166. PMCID:3851022. DOI:10.1016/j.jacc.2013.04.080.
  113. DeMatteo RP, **Ballman KV**, Antonescu CR, Corless C, Kolesnikova V, von Mehren M, McCarter MD, Norton J, Maki RG, Pisters PW, Demetri GD, Brennan MF, Owzar K, American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team for the Alliance for Clinical Trials in Oncology. Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial. *Ann Surg*. 2013 Sep; 258(3):422-9. PMID:23860199. PMCID:4041735. DOI:10.1097/SLA.0b013e3182a15eb7.
  114. Wildiers H, Mauer M, Pallis A, Hurria A, Mohile SG, Luciani A, Curigliano G, Extermann M, Lichtman SM, **Ballman K**, Cohen HJ, Muss H, Wedding U. End points and trial design in geriatric oncology research: a joint European organisation for research and treatment of cancer--Alliance for Clinical Trials in Oncology--International Society Of Geriatric Oncology position article. *J Clin Oncol*. 2013 Oct 10; 31(29):3711-8. Epub 2013 Sep 09. PMID:24019549. DOI:10.1200/JCO.2013.49.6125.
  115. Dueck AC, Reinholz MM, Geiger XJ, Tenner K, **Ballman K**, Jenkins RB, Riehle D, Chen B, McCullough AE, Davidson NE, Martino S, Sledge GW, Kaufman PA, Kutteh LA, Gralow J, Harris LN, Ingle JN, Lingle WL, Perez EA. Impact of c-MYC protein expression on outcome of patients with early-stage HER2+ breast cancer treated with adjuvant trastuzumab NCCTG (alliance) N9831. *Clin Cancer Res*. 2013 Oct 15; 19(20):5798-807. Epub 2013 Aug 21. PMID:23965903. PMCID:3805021. DOI:10.1158/1078-0432.CCR-13-0558.
  116. Karnes RJ, Bergstralh EJ, Davicioni E, Ghadessi M, Buerki C, Mitra AP, Crisan A, Erho N, Vergara IA, Lam LL, Carlson R, Thompson DJ, Haddad Z, Zimmermann B, Sierocinski T, Triche TJ, Kollmeyer T, **Ballman KV**, Black PC, Klee GG, Jenkins RB. Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population. *J Urol*. 2013 Dec; 190(6):2047-53. Epub 2013 Jun 11. PMID:23770138. PMCID:4097302. DOI:10.1016/j.juro.2013.06.017.
  117. Barginear MF, Muss H, Kimmick G, Owusu C, Mrozek E, Shahrokni A, **Ballman K**, Hurria A. Breast cancer and aging: Results of the U13 conference breast cancer panel. *Breast Cancer Res Treat*. 2014; 146(1):1-6.
  118. Joensuu H, Eriksson M, Hall KS, Hartmann JT, Pink D, Schutte J, Ramadori G, Hohenberger P, Duyster J, Al-Batran SE, Schlemmer M, Bauer S, Wardelmann E, Sarlomo-Rikala M, Nilsson B, Sihto H, **Ballman KV**, Leinonen M, Dematteo RP, Reichardt P. Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib. *Cancer*. 2014; 120(15):2325-33.
  119. Batdorf NJ, Mubang R, Whitney G, **Ballman K**, Lovely J, Grubbs P, Lisa B, Hinckley A, Lemaine V, Saint-Cyr M. Abstract 113: Comparison of Outcomes for Patients Undergoing Free Flap Autologous Breast Reconstruction Utilizing a Multimodal Enhanced Recovery Pathway versus Traditional Care. *Plast Reconstr Surg*. 2014 Mar; 133(3 Suppl):130. PMID:25942224. DOI:10.1097/01.prs.0000444938.78110.c2.
  120. Grogan EL, Deppen SA, **Ballman KV**, Andrade GM, Verdial FC, Aldrich MC, Chen CL, Decker PA, Harpole DH, Cerfolio RJ, Keenan RJ, Jones DR, D'Amico TA, Shrager JB, Meyers BF, Putnam JB Jr. Accuracy of fluorodeoxyglucose-positron emission tomography within the clinical practice of the American College of Surgeons Oncology Group Z4031 trial to diagnose clinical stage I non-small cell lung cancer. *Ann Thorac Surg*. 2014 Apr; 97(4):1142-8. Epub 2014 Feb 25. PMID:24576597. PMCID:4008142. DOI:10.1016/j.athoracsur.2013.12.043.
  121. Corless CL, **Ballman KV**, Antonescu CR, Kolesnikova V, Maki RG, Pisters PW, Blackstein ME, Blanke CD, Demetri GD, Heinrich MC, von Mehren M, Patel S, McCarter MD, Owzar K, DeMatteo RP. Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial. *J Clin Oncol*. 2014 May 20; 32(15):1563-70. Epub 2014 Mar 17. PMID:24638003. PMCID:4026579. DOI:10.1200/JCO.2013.51.2046.
  122. Hurria A, Dale W, Mooney M, Rowland JH, **Ballman KV**, Cohen HJ, Muss HB, Schilsky RL, Ferrell B, Extermann M, Schmader KE, Mohile SG. Designing Therapeutic Clinical Trials for Older and Frail

- Adults With Cancer: U13 Conference Recommendations. *J Clin Oncol*. 2014 Aug 20;32(24):2587-94. Epub 2014 Jul 29. PMID:25071116. PMCID:4129504. DOI:10.1200/JCO.2013.55.0418.
123. Klepin HD, Pitcher BN, **Ballman KV**, Kornblith AB, Hurria A, Winer EP, Hudis C, Cohen HJ, Muss HB, Kimmick GG. Comorbidity, chemotherapy toxicity, and outcomes among older women receiving adjuvant chemotherapy for breast cancer on a clinical trial: CALGB 49907 and CALGB 361004 (alliance). *J Oncol Pract*. 2014 Sep; 10(5):e285-92. Epub 2014 Jul 29. PMID:25074878. PMCID:4161730. DOI:10.1200/JOP.2014.001388.
  124. Cheng H, **Ballman K**, Vassilakopoulou M, Dueck AC, Reinholz MM, Tenner K, Gralow J, Hudis C, Davidson NE, Fountzilas G, McCullough AE, Chen B, Psyri A, Rimm DL, Perez EA. EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial. *Br J Cancer*. 2014 Sep 9; 111(6):1065-71. Epub 2014 Aug 12. PMID:25117817. DOI:10.1038/bjc.2014.442.
  125. Boughey JC, McCall LM, **Ballman KV**, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, Leitch AM, Flippo-Morton T, Hunt KK. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial. *Ann Surg*. 2014 Oct; 260(4):608-14; discussion 614-6. PMID:25203877. PMCID:4159769. DOI:10.1097/SLA.0000000000000924.
  126. Degen AC, Hoskin TL, Brahmabhatt RD, Warren-Peled A, Loprinzi M, Pavey ES, Boughey JC, Hieken TJ, Jacobson S, Lemaine V, Jakub JW, Irwin C, Foster RD, Sbitany H, Saint-Cyr M, Duralde E, Ramaker S, Chin R, Sieg M, Wildeman M, Scow JS, Patel R, **Ballman K**, Baddour LM, Esserman LJ. Randomized trial of drain antisepsis after mastectomy and immediate prosthetic breast reconstruction. *Ann Surg Oncol*. 2014 Oct; 21(10):3240-8. Epub 2014 Aug 06. PMID:25096386. PMCID:4373621. DOI:10.1245/s10434-014-3918-9.
  127. Onkendi EO, Jimenez RE, Spears GM, Harmsen WS, **Ballman KV**, Hieken TJ. Surgical treatment of borderline and malignant phyllodes tumors: the effect of the extent of resection and tumor characteristics on patient outcome. *Ann Surg Oncol*. 2014 Oct; 21(10):3304-9. Epub 2014 Jul 18. PMID:25034817. DOI:10.1245/s10434-014-3909-x.
  128. Norton N, Olson RM, Pegram M, Tenner K, **Ballman KV**, Clynes R, Knutson KL, Perez EA. Association studies of Fcγ receptor polymorphisms with outcome in HER2+ breast cancer patients treated with trastuzumab in NCCTG (Alliance) Trial N9831. *Cancer Immunol Res*. 2014 Oct; 2(10):962-9. Epub 2014 Jul 02. PMID:24989892. PMCID:4215796. DOI:10.1158/2326-6066.CIR-14-0059.
  129. Reardon DA, **Ballman KV**, Buckner JC, Chang SM, Ellingson BM. Impact of imaging measurements on response assessment in glioblastoma clinical trials. *Neuro Oncol*. 2014 Oct; 16 Suppl 7:vii24-35. PMID:25313236. PMCID:4195531. DOI:10.1093/neuonc/nou286.
  130. Wen PY, Cloughesy TF, Ellingson BM, Reardon DA, Fine HA, Abrey L, **Ballman K**, Bendszuz M, Buckner J, Chang SM, Prados MD, Pope WB, Gregory Sorensen A, van den Bent M, Yung WK. Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD). *Neuro Oncol*. 2014 Oct; 16 Suppl 7:vii36-47. PMID:25313237. PMCID:4195530. DOI:10.1093/neuonc/nou226.
  131. Jagsi R, Chadha M, Moni J, **Ballman K**, Laurie F, Buchholz TA, Giuliano A, Haffty BG. Radiation field design in the ACOSOG Z0011 (Alliance) Trial. *J Clin Oncol*. 2014 Nov 10; 32(32):3600-6. Epub 2014 Aug 18. PMID:25135994. PMCID:4220042. DOI:10.1200/JCO.2014.56.5838.
  132. Necela BM, Crozier JA, Andorfer CA, Lewis-Tuffin L, Kachergus JM, Geiger XJ, Kalari KR, Serie DJ, Sun Z, Aspita AM, O'Shannessy DJ, Maltzman JD, McCullough AE, Pockaj BA, Cunliffe HE, **Ballman KV**, Thompson EA, Perez EA. Folate Receptor-alpha (FOLR1) Expression and Function in Triple Negative Tumors. *PLoS One*. 2015; 10(3):e0122209. Epub 2015 Mar 27. PMID:25816016. PMCID:4376802. DOI:10.1371/journal.pone.0122209.
  133. Grotz TE, Puig CA, Perkins S, **Ballman K**, Hieken TJ. Management of regional lymph nodes in the elderly melanoma patient: patient selection, accuracy and prognostic implications. *Eur J Surg Oncol*. 2015 Jan; 41(1):157-64. Epub 2014 Oct 30. PMID:25468751. DOI:10.1016/j.ejso.2014.10.051.
  134. Alexander BM, Galanis E, Yung WK, **Ballman KV**, Boyett JM, Cloughesy TF, Degroot JF, Huse JT, Mann B, Mason W, Mellingerhoff IK, Mikkelsen T, Mischel PS, O'Neill BP, Prados MD, Sarkaria JN, Tawab-Amiri A, Trippa L, Ye X, Ligon KL, Berry DA, Wen PY. Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group. *Neuro Oncol*.

135. Boughey JC, **Ballman KV**, Hunt KK, McCall LM, Mittendorf EA, Ahrendt GM, Wilke LG, Le-Petross HT. Axillary Ultrasound After Neoadjuvant Chemotherapy and Its Impact on Sentinel Lymph Node Surgery: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance). *J Clin Oncol*. 2015 Feb 02. PMID:25646192. DOI:10.1200/JCO.2014.57.8401.
136. Batdorf NJ, Lemaine V, Lovely JK, **Ballman KV**, Goede WJ, Martinez-Jorge J, Booth-Kowalczyk AL, Grubbs PL, Bungum LD, Saint-Cyr M. Enhanced recovery after surgery in microvascular breast reconstruction. *J Plast Reconstr Aesthet Surg*. 2015 Mar; 68(3):395-402. Epub 2014 Nov 21. PMID:25488326. DOI:10.1016/j.bjps.2014.11.014.
137. Perez EA, Thompson EA, **Ballman KV**, Anderson SK, Asmann YW, Kalari KR, Eckel-Passow JE, Dueck AC, Tenner KS, Jen J, Fan JB, Geiger XJ, McCullough AE, Chen B, Jenkins RB, Sledge GW, Winer EP, Gralow JR, Reinholz MM. Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial. *J Clin Oncol*. 2015 Mar 1; 33(7):701-8. Epub 2015 Jan 20. PMID:25605861. PMCID:4334774. DOI:10.1200/JCO.2014.57.6298.
138. Mohan AT, Rammos CK, Gaba P, Schupbach J, Goede WJ, **Ballman K**, Batdorf N, Cheng A, Saint-Cyr M. Modified aesthetic abdominoplasty approach in perforator free-flap breast reconstruction: Impact of drain free donor site on patient outcomes. *J Plast Reconstr Aesthet Surg*. 2015. 68(6):800-809. PMID:25843908. DOI:10.1016/j.bjps.2015.03.008.
139. Laungani AT, Van Alphen N, Christner JA, Lachman N, Pawlina W, **Ballman KV**, Saint-Cyr M. Three-dimensional CT angiography assessment of the impact of the dermis and the subdermal plexus in DIEP flap perfusion. *J Plast Reconstr Aesthet Surg*. 2015 Apr; 68(4):525-30. Epub 2015 Jan 07. PMID:25665491. DOI:10.1016/j.bjps.2014.12.004.
140. Mittendorf EA, **Ballman KV**, McCall LM, Yi M, Sahin AA, Bedrosian I, Hansen N, Gabram S, Hurd T, Giuliano AE, Hunt KK. Evaluation of the Stage IB Designation of the American Joint Committee on Cancer Staging System in Breast Cancer. *J Clin Oncol*. 2015 Apr 1; 33(10):1119-27. Epub 2014 Dec 08. PMID:25488970. PMCID:4372850. DOI:10.1200/JCO.2014.57.2958.
141. Jatoi A, Muss H, Allred JB, Cohen HJ, **Ballman K**, Hopkins JO, Gajra A, Lafky J, Wolff A, Kottschade L, Gralow J, Hurria A. Psychooncology. 2015 May 20. doi: 10.1002/pon.3850. [Epub ahead of print] PMID: 25994447
142. O'Sullivan CC, Bradbury I, Campbell C, Spielmann M, Perez EA, Joensuu H, Costantino JP, Delaloge S, Rastogi P, Zardavas D, **Ballman KV**, Holmes E, de Azambuja E, Piccart-Gebhart M, Zujewski JA, Gelber RD. Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors  $\leq 2$  cm: A Meta-Analysis of the Randomized Trastuzumab Trials. *J Clin Oncol*. 2015 Aug 20;33(24):2600-8. doi: 10.1200/JCO.2015.60.8620. PMID: 26101239
143. **Ballman KV**. Biomarker: Predictive or Prognostic? *J Clin Oncol*. 2015 Nov 20;33(33):3968-71. doi: 10.1200/JCO.2015.63.3651. Epub 2015 Sep 21. PubMed PMID: 26392104.
144. Zielinski MD, Kuntz MM, Polites SF, Boggust A, Nelson H, Khasawneh MA, Jenkins DH, Harmsen S, **Ballman KV**, Pieper R. A prospective analysis of urinary tract infections among elderly trauma patients. *J Trauma Acute Care Surg*. 2015 Oct;79(4):638-42. doi: 10.1097/TA.0000000000000796. PubMed PMID: 26402539; PubMed Central PMCID: PMC4582427.
145. **Ballman KV**. Biomarker-based trials in neuro-oncology. *Chin Clin Oncol*. 2015 Sep;4(3):38. doi: 10.3978/j.issn.2304-3865.2015.09.04. PubMed PMID: 26408305.
146. Perez EA, Baehner FL, Butler SM, Thompson EA, Dueck AC, Jamshidian F, Cherbavaz D, Yoshizawa C, Shak S, Kaufman PA, Davidson NE, Gralow J, Asmann YW, **Ballman KV**. The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831. *Breast Cancer Res*. 2015 Oct 1;17(1):133. doi: 10.1186/s13058-015-0643-7. PubMed PMID: 26429296; PubMed Central PMCID: PMC4589954.
147. Perez EA, **Ballman KV**, Tenner KS, Thompson EA, Badve SS, Bailey H, Baehner FL. Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in

- Patients With Early-Stage HER2-Positive Breast Cancer. *JAMA Oncol.* 2016 Jan 1;2(1):56-64. doi: 10.1001/jamaoncol.2015.3239. PubMed PMID: 26469139; PubMed Central PMCID: PMC4713247.
148. Huang RY, Rahman R, **Ballman KV**, Felten SJ, Anderson SK, Ellingson BM, Nayak L, Lee EQ, Abrey LE, Galanis E, Reardon DA, Pope WB, Cloughesy TF, Wen PY. The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab. *Clin Cancer Res.* 2015 Oct 21. [Epub ahead of print] PubMed PMID: 26490307.
  149. Park MS, Xue A, Spears GM, Halling TM, Ferrara MJ, Kuntz MM, Dhillon SK, Jenkins DH, Harmsen WS, **Ballman KV**, Harrison P, Heit JA. Thrombin generation and procoagulant microparticle profiles after acute trauma: A prospective cohort study. *J Trauma Acute Care Surg.* 2015 Nov;79(5):726-31. doi: 10.1097/TA.0000000000000839. PubMed PMID: 26496097; PubMed Central PMCID: PMC4621757.
  150. Gupta SK, Kizilbash SH, Carlson BL, Mladek AC, Boakye-Agyeman F, Bakken KK, Pokorny JL, Schroeder MA, Decker PA, Cen L, Eckel-Passow JE, Sarkar G, Ballman KV, Reid JM, Jenkins RB, Verhaak RG, Sulman EP, Kitange GJ, Sarkaria JN. Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma. *J Natl Cancer Inst.* 2015 Nov 27;108(5). pii: djv369. doi: 10.1093/jnci/djv369. Print 2015 May. PubMed PMID: 26615020.
  151. Boughey JC, **Ballman KV**, Le-Petross HT, McCall LM, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, Feliberti EC, Hunt KK. Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0-T4, N1-N2) Who Receive Neoadjuvant Chemotherapy: Results From ACOSOG Z1071 (Alliance). *Ann Surg.* 2015 Nov 26. [Epub ahead of print] PubMed PMID: 26649589.
  152. Chen J, Ryu E, Hatchcock M, **Ballman K**, Chia N, Olson JE, Nelson H. Impact of demographics on human gut microbial diversity in a US Midwest population. *PeerJ* 2016 4:e1514; DOI 10.7717/peerj.1514
  153. Zielinski MD, Kuntz M, Zhang X, Zagar AE, Khasawneh MA, Zendejas B, Polites SF, Ferrara M, Harmsen WS, **Ballman KV**, Park MS, Schiller HJ, Dries D, Jenkins DH. Botulinum toxin A-induced paralysis of the lateral abdominal wall after damage-control laparotomy: A multi-institutional, prospective, randomized, placebo-controlled pilot study. *J Trauma Acute Care Surg.* 2016 Feb;80(2):237-42. doi: 10.1097/TA.0000000000000917. PMID: 26813298.
  154. Haffty BG, McCall LM, **Ballman KV**, McLaughlin S, Jagsi R, Ollila DW, Hunt KK, Buchholz TA, Boughey JC. Patterns of Local-Regional Management Following Neoadjuvant Chemotherapy in Breast Cancer: Results From ACOSOG Z1071 (Alliance). *Int J Radiat Oncol Biol Phys.* 2016 Mar 1;94(3):493-502. doi: 10.1016/j.ijrobp.2015.11.005. PMID: 26867878; PMCID: PMC4752720.
  155. Shoag J, Halpern JA, Lee DJ, Mittal S, **Ballman KV**, Barbieri CE, Hu JC. Decline in prostate cancer screening by primary care physicians: an analysis of trends in the use of digital rectal examination and prostate specific antigen testing. *J Urol.* 2016 Oct;196(4):1047-52. doi: 10.1016/j.juro.2016.03.171. PMID: 27060052
  156. Knutson KL, Clynes R, Shreeder B, Yeramian P, Kemp K, **Ballman K**, Tenner KS, Erskine CL, Norton N, Northfelt DW, Tan W, Calfa C, Pegram MD, Mittendorf EA, Perez EA. Improved survival of HER2+ breast cancer patients treated with trastuzumab and chemotherapy is associated with host antibody immunity against the HER2 intracellular domain. *Cancer Res.* 2016 Jul 1;76(13):3702-10. PMID: 27197192
  157. Nipp RD, Yao NA, Lowenstein LM, Buckner JC, Parker IR, Gajra A, Morrison VA, Dale W, **Ballman KV**. Pragmatic study designs for older adults with cancer: Report from the U13 conference. *J Geriatr Oncol.* 2016 Jul;7(4):234-41. Review. PubMed PMID: 27197914
  158. Simmons RM, **Ballman KV**, Cox C, Carp N, Sabol J, Hwang RF, Attai D, Sabel M, Nathanson D, Kenler A, Gold L, Kaufman C, Han L, Bleznak A, Stanley Smith J, Holmes D, Fornage B, Le-Petross C, Hoda S, McCall L, Hunt KK; ACOSOG investigators. A Phase II Trial Exploring the Success of Cryoablation Therapy in the Treatment of Invasive Breast Carcinoma: Results from ACOSOG (Alliance) Z1072. *Ann Surg Oncol.* 2016 Aug;23(8):2438-45. PMID: 27221361
  159. Osarogiagbon RU, Decker PA, **Ballman K**, Wigle D, Allen MS, Darling GE. Survival Implications of Variation in the Thoroughness of Pathologic Lymph Node Examination in American College of

Surgeons Oncology Group Z0030 (Alliance). *Ann Thorac Surg*. 2016 Aug;102(2):363-9. PMID: 27262908

160. Park MS, Perkins SE, Spears GM, Ashrani AA, Leibson CL, Boos CM, Harmsen WS, Jenkins DH, Bailey KR, **Ballman KV**, Heit JA. Risk factors for venous thromboembolism after acute trauma: A population-based case-cohort study. *Thromb Res*. 2016 Aug;144:40-5. doi: 10.1016/j.thromres.2016.03.026. PMID: 27284980
161. Aho JM, Nourallah A, Samaha MJ, Antiel RM, Dupont SC, **Ballman KV**, Sloan JA, Bingener J. Patient-Reported Outcomes after Laparoscopic Ventral Hernia Repair. *Am Surg*. 2016 Jun;82(6):550-6. PMID: 27305889
162. Brown PD, Jaeckle K, **Ballman KV**, Farace E, Cerhan JH, Anderson SK, Carrero XW, Barker FG 2nd, Deming R, Burri SH, Ménard C, Chung C, Stieber VW, Pollock BE, Galanis E, Buckner JC, Asher AL. Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial. *JAMA*. 2016 Jul 26;316(4):401-9. doi: 10.1001/jama.2016.9839. PubMed PMID: 27458945.
163. Shah MV, Wiktor AE, Meyer RG, Tenner KS, **Ballman KV**, Green SJ, Sukov WR, Ketterling RP, Perez EA, Jenkins RB. Change in Pattern of HER2 Fluorescent in Situ Hybridization (FISH) Results in Breast Cancers Submitted for FISH Testing: Experience of a Reference Laboratory Using US Food and Drug Administration Criteria and American Society of Clinical Oncology and College of American Pathologists Guidelines. *J Clin Oncol*. 2016 Oct 10;34(29):3502-3510. PubMed PMID: 27458302.
164. Giuliano AE, **Ballman K**, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM, Saha S, Morrow M, Hunt KK. Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: Long-term Follow-up From the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial. *Ann Surg*. 2016 Sep;264(3):413-20. doi: 10.1097/SLA.0000000000001863.
165. Warner ET, **Ballman KV**, Strand C, Boughey JC, Buzdar AU, Carey LA, Sikov WM, Partridge AH. Impact of race, ethnicity, and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer: a pooled analysis of four prospective Alliance clinical trials (A151426). *Breast Cancer Res Treat*. 2016 Aug;159(1):109-18. PubMed PMID: 27449492
166. Halpern JA, Shoag JE, Mittal S, Oromendia C, **Ballman KV**, Hershman DL, Wright JD, Tina Shih YC, Nguyen PL, Hu JC. Prognostic Significance of Digital Rectal Examination and Prostate Specific Antigen in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Arm. *J Urol*. 2017 Feb;197(2):363-368. doi: 10.1016/j.juro.2016.08.092. PubMed PMID: 27569432.
167. Laungani AT, Christner J, Primus JA, Lachman N, **Ballman KV**, Mohan A, Saint-Cyr M. Study of the Impact of the Location of a Perforator in the Perfusion of a Perforator Flap: The Concept of "Angle of Perfusion". *J Reconstr Microsurg*. 2017 Jan;33(1):49-58. PMID: 27636539
168. Perez EA, **Ballman KV**, Mashadi-Hosseini A, Tenner KS, Kachergus JM, Norton N, Necela BM, Carr JM, Ferree S, Perou CM, Baehner F, Cheang MC, Thompson EA. Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breast Tumors from the NCCTG (Alliance) N9831 Trial. *J Natl Cancer Inst*. 2016 Oct 28;109(2). pii: djw207.
169. Halpern JA, Shoag JE, Artis AS, **Ballman KV**, Sedrakyan A, Hershman DL, Wright JD, Shih YC, Hu JC. National Trends in Prostate Biopsy and Radical Prostatectomy Volumes Following the United States Preventative Services Task Force Guidelines Against Prostate-Specific Antigen Screening. *JAMA Surg*. 2017 Feb 1;152(2):192-198. doi: 10.1001/jamasurg.2016.3987. PubMed PMID: 27806151.
170. Lewicki P, Shoag J, Golombos DM, Oromendia C, **Ballman KV**, Halpern JA, Stone BV, O'Malley P, Barbieri CE, Scherr DS. Prognostic significance of a negative prostate biopsy: An analysis of subjects enrolled in a prostate cancer screening trial. *J Urol*. 2017 Apr;197(4):1014-1019. doi: 10.1016/j.juro.2016.11.002. PubMed PMID: 27836710
171. Argenta PA, **Ballman KV**, Geller MA, Carson LF, Ghebre R, Mullany SA, Teoh DG, Winterhoff BJ, Rivard CL, Erickson BK. The effect of photobiomodulation on chemotherapy-induced peripheral neuropathy: A randomized, sham-controlled clinical trial. *Gynecol Oncol*. 2017 Jan;144(1):159-166. doi:10.1016/j.ygyno.2016.11.013. PubMed PMID: 27887804.

172. Ashamalla H, Guirguis A, McCool K, McVorrán S, Mattes M, Metzger D, Oromendia C, **Ballman KV**, Mokhtar B, Tchelebi M, Katsoulakis E, Rafla S. Brachytherapy improves outcomes in young men ( $\leq 60$  years) with prostate cancer: A SEER analysis. *Brachytherapy*. 2017 Jul - Aug;16(4):916-918. doi: 10.1016/j.brachy.2016.12.010. PubMed PMID: 28139417.
173. Kimmick GG, Major B, Clapp J, Sloan J, Pitcher B, **Ballman K**, Barginear M, Freedman RA, Artz A, Klepin HD, Lafky JM, Hopkins J, Winer E, Hudis C, Muss H, Cohen H, Jatoi A, Hurria A, Mandelblatt J. Using ePrognosis to estimate 2-year all-cause mortality in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503). *Breast Cancer Res Treat*. 2017 Jun;163(2):391-398.. doi: 10.1007/s10549-017-4188-6. PubMed PMID: 28283904.
174. Perez EA, **Ballman KV**, Mashadi-Hosseini A, Tenner KS, Kachergus JM, Norton N, Necela BM, Carr JM, Ferree S, Perou CM, Baehner F, Cheang MC, Thompson EA. Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breast Tumors from the NCCTG (Alliance) N9831 Trial. *J Natl Cancer Inst*. 2017 Feb 1;109(2):1-8. doi: 10.1093/jnci/djw207. PubMed PMID: 28376219.
175. Grossman SA, Schreck KC, **Ballman K**, Alexander B. Point/counterpoint: randomized versus single-arm phase II clinical trials for patients with newly diagnosed glioblastoma. *Neuro Oncol*. 2017 Apr 1;19(4):469-474. doi: 10.1093/neuonc/nox030. PubMed PMID: 28388713.
176. Reinholz MM, Chen B, Dueck AC, Tenner K, **Ballman K**, Riehle D, Jenkins RB, Geiger XJ, McCullough AE, Perez EA. IGF1R Protein Expression Is Not Associated with Differential Benefit to Concurrent Trastuzumab in Early-Stage HER2(+) Breast Cancer from the North Central Cancer Treatment Group (Alliance) Adjuvant Trastuzumab Trial N9831. *Clin Cancer Res*. 2017 Aug 1;23(15):4203-4211. doi: 10.1158/1078-0432.CCR-15-0574. PubMed PMID: 28533226.
177. Antonarakis ES, Tagawa ST, Galletti G, Worroll D, **Ballman K**, Vanhuyse M, Sonpavde G, North S, Albany C, Tsao CK, Stewart J, Zaher A, Szatrowski T, Zhou W, Gjyzezi A, Tasaki S, Portella L, Bai Y, Lannin TB, Suri S, Gruber CN, Pratt ED, Kirby BJ, Eisenberger MA, Nanus DM, Saad F, Giannakakou P; TAXYNERGY Investigators. Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer. *J Clin Oncol*. 2017 Oct 1;35(28):3181-3188. doi: 10.1200/JCO.2017.72.4138. PubMed PMID: 28632486.
178. Boughey JC, **Ballman KV**, McCall LM, Mittendorf EA, Symmans WF, Julian TB, Byrd D, Hunt KK. Tumor Biology and Response to Chemotherapy Impact Breast Cancer-specific Survival in Node-positive Breast Cancer Patients Treated With Neoadjuvant Chemotherapy: Long-term Follow-up From ACOSOG Z1071 (Alliance). *Ann Surg*. 2017 Oct;266(4):667-676. doi: 10.1097/SLA.0000000000002373. PubMed PMID: 28657941.
179. Brown PD, **Ballman KV**, Cerhan JH, Anderson SK, Carrero XW, Whitton AC, Greenspoon J, Parney IF, Laack NNI, Ashman JB, Bahary JP, Hadjipanayis CG, Urbanic JJ, Barker FG 2nd, Farace E, Khuntia D, Giannini C, Buckner JC, Galanis E, Roberge D. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC-3): a multicentre, randomised, controlled, phase 3 trial. *Lancet Oncol*. 2017 Aug;18(8):1049-1060. doi: 10.1016/S1470-2045(17)30441-2. PubMed PMID: 28687377.
180. Giuliano AE, **Ballman KV**, McCall L, Beitsch PD, Brennan MB, Kelemen PR, Ollila DW, Hansen NM, Whitworth PW, Blumencranz PW, Leitch AM, Saha S, Hunt KK, Morrow M. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial. *JAMA*. 2017 Sep 12;318(10):918-926. doi: 10.1001/jama.2017.11470. PubMed PMID: 28898379.
181. Churilla TM, **Ballman KV**, Brown PD, Twohy EL, Jaeckle K, Farace E, Cerhan JH, Anderson SK, Carrero XW, Garces YI, Barker FG 2nd, Deming R, Dixon JG, Burri SH, Chung C, Ménard C, Stieber VW, Pollock BE, Galanis E, Buckner JC, Asher AL. Stereotactic Radiosurgery With or Without Whole-Brain Radiation Therapy for Limited Brain Metastases: A Secondary Analysis of the North Central Cancer Treatment Group N0574 (Alliance) Randomized Controlled Trial. *Int J Radiat Oncol Biol Phys*. 2017 Dec 1;99(5):1173-1178. doi: 10.1016/j.ijrobp.2017.07.045. [Epub ahead of print] PubMed PMID: 28939223.
182. Galanis E, Anderson SK, Miller CR, Sarkaria JN, Jaeckle K, Buckner JC, Ligon KL, **Ballman KV**, Moore DF Jr, Nebozhyn M, Loboda A, Schiff D, Ahluwalia MS, Lee EQ, Gerstner ER, Lesser GJ, Prados M, Grossman SA, Cerhan J, Giannini C, Wen PY; Alliance for Clinical Trials in Oncology and ABTC. Phase I/II Trial of Vorinostat Combined with Temozolomide and Radiation Therapy for Newly

Diagnosed Glioblastoma: Final Results of Alliance N0874/ABTC 02. *Neuro Oncol.* 2018 Mar 27;20(4):546-556. [Epub ahead of print] PubMed PMID: 29016887.

183. Chen J, King E, Deek R, Wei Z, Yu Y, Grill D, **Ballman K**, Stengle O. An omnibus test for differential distribution analysis of microbiome sequencing data. *Bioinformatics* 2018. 34: 643-651. doi: 10.1093/bioinformatics/btx650. PMID: 29040451
184. Gaudino M, Alexander JH, Bakaeen FG, **Ballman K**, Barili F, Calafiore AM, Davierwala P, Goldman S, Kappetein P, Lorusso R, Mylotte D, Pagano D, Ruel M, Schwann T, Suma H, Taggart DP, Tranbaugh RF, Fremes S. Randomized comparison of the clinical outcome of single versus multiple arterial grafts: the ROMA trial-rationale and study protocol. *Eur J Cardiothorac Surg.* 2017 Dec 1;52(6):1031-1040. doi: 10.1093/ejcts/ezx358. [Epub ahead of print] PubMed PMID: 29059371.
185. Halpern JA, Oromendia C, Shoag JE, Mittal S, Cosiano MF, **Ballman KV**, Vickers AJ, Hu JC. Utility of Digital Rectal Examination (DRE) as an Adjunct to Prostate Specific Antigen (PSA) in the Detection of Clinically Significant Prostate Cancer. *J Urol.* 2018 Apr;199(4):947-953. doi: 10.1016/j.juro.2017.10.021. [Epub ahead of print] PubMed PMID: 29061540.
186. Le-Petross HT, McCall LM, Hunt KK, Mittendorf EA, Ahrendt GM, Wilke LG, **Ballman KV**, Boughey JC. Axillary Ultrasound Identifies Residual Nodal Disease After Chemotherapy: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance). *AJR Am J Roentgenol.* 2018 Jan 30:1-8. doi: 10.2214/AJR.17.18295. [Epub ahead of print] PubMed PMID: 29381381.
187. Chen J, Oromendia C, Halpern JA, **Ballman KV**. National trends in management of localized prostate cancer: A population based analysis 2004-2013. *Prostate.* 2018; 78(7):512-520. doi: 10.1002/pros.23496. [Epub ahead of print] PubMed PMID: 29542178.
188. Gajra A, McCall L, Muss HB, Cohen HJ, Jatoi A, **Ballman KV**, Partridge AH, Sutton L, Parker BA, Magrinat G, Klepin HD, Lafky JM, Hurria A. The preference to receive chemotherapy and cancer-related outcomes in older adults with breast cancer CALGB 49907 (alliance). *J Geriatr Oncol.* 2018; 9(3):221-227. doi: 10.1016/j.jgo.2018.02.003. [Epub ahead of print] PubMed PMID: 29602735.
189. Schumacher JR, Neuman HB, Chang GJ, Kozower BD, Edge SB, Yu M, Vanness DJ, Si Y, Jacobs EA, Francescatti AB, Spears PA, Havlena J, Adesoye T, McKellar D, Winchester D, Burnside ES, Greenberg CC; Alliance ACS-CRP CCDR Breast Cancer Surveillance Working Group. A National Study of the Use of Asymptomatic Systemic Imaging for Surveillance Following Breast Cancer Treatment (AFT-01). *Ann Surg Oncol.* 2018; 25(9):2587-2595. doi: 10.1245/s10434-018-6496-4. PubMed PMID: 29777402.
190. Díaz I, Savenkov O, **Ballman K**; Targeted learning ensembles for optimal individualized treatment rules with time-to-event outcomes, *Biometrika*, asy017, <https://doi.org/10.1093/biomet/asy017>
191. Li D, McCall LM, Hahn OM, Hudis CA, Cohen HJ, Muss HB, Jatoi A, Lafky JM, **Ballman KV**, Winer EP, Tripathy D, Schneider B, Barry W, Dickler MN, Hurria A. Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study. *Breast Cancer Res Treat.* 2018 171(2):325-334. doi: 10.1007/s10549-018-4828-5. PubMed PMID: 29789969.
192. Schumacher JR, Neuman HB, Chang GJ, Kozower BD, Edge SB, Yu M, Vanness DJ, Si Y, Jacobs EA, Francescatti AB, Spears PA, Havlena J, Adesoye T, McKellar D, Winchester D, Burnside ES, Greenberg CC; Alliance ACS-CRP CCDR Breast Cancer Surveillance Working Group. A National Study of the Use of Asymptomatic Systemic Imaging for Surveillance Following Breast Cancer Treatment (AFT-01). *Ann Surg Oncol.* 2018 May 17. doi: 10.1245/s10434-018-6496-4. [Epub ahead of print] PubMed PMID: 29777402.
193. Li D, McCall LM, Hahn OM, Hudis CA, Cohen HJ, Muss HB, Jatoi A, Lafky JM, **Ballman KV**, Winer EP, Tripathy D, Schneider B, Barry W, Dickler MN, Hurria A. Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study. *Breast Cancer Res Treat.* 2018;171(2):325-334. doi: 10.1007/s10549-018-4828-5. Epub 2018 May 22. PMID: 29789969
194. Norton N, Fox N, McCarl CA, Tenner KS, **Ballman K**, Erskine CL, Necela BM, Northfelt D, Tan WW, Calfa C, Pegram M, Colon-Otero G, Perez EA, Clynes R, Knutson KL. Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer. *Breast Cancer Res.* 2018 Jun 14;20(1):52. doi: 10.1186/s13058-018-0989-8. PubMed PMID: 29898752.

195. Armer JM, **Ballman KV**, McCall L, Armer NC, Sun Y, Udmuangpia T, Hunt KK, Mittendorf EA, Byrd DR, Julian TB, Boughey JC. Lymphedema symptoms and limb measurement changes in breast cancer survivors treated with neoadjuvant chemotherapy and axillary dissection: results of American College of Surgeons Oncology Group (ACOSOG) Z1071 (Alliance) substudy. *Support Care Cancer*. 2019 Feb;27(2):495-503. doi: 10.1007/s00520-018-4334-7. [Epub ahead of print] PubMed PMID: 29980907
196. Rosenkranz KM, **Ballman K**, McCall L, Kubicky C, Cuttino L, Le-Petross H, Hunt KK, Giuliano A, Van Zee KJ, Haffty B, Boughey JC. The Feasibility of Breast-Conserving Surgery for Multiple Ipsilateral Breast Cancer: An Initial Report from ACOSOG Z11102 (Alliance) Trial. *Ann Surg Oncol*. 2018 Oct;25(10):2858-2866. doi: 10.1245/s10434-018-6583-6. [Epub ahead of print] PubMed PMID: 29987605.
197. Desai P, Mencia-Trinchant N, Savenkov O, Simon MS, Cheang G, Lee S, Samuel M, Ritchie EK, Guzman ML, **Ballman KV**, Roboz GJ, Hassane DC. Somatic mutation precede acute myeloid leukemia years before diagnosis. *Nat Med*. 2018 Jul;24(7):1015-1023. doi: 10.1038/s41591-018-0081-z. Epub 2018 Jul 9. PubMed PMID: 29988143.
198. Ma KC, Schenck EJ, Siempos II, Cloonan SM, Finkelstein EJ, Pabon MA, Oromendia C, **Ballman KV**, Baron RM, Fredenburgh LE, Higuera A, Lee JY, Chung CR, Jeon K, Yang JH, Howrylak JA, Huh JW, Suh GY, Choi AM. Circulating RIPK3 levels are associated with mortality and organ failure during critical illness. *JCI Insight*. 2018 Jul 12;3(13). pii: 99692. doi: 10.1172/jci.insight.99692. [Epub ahead of print] PubMed PMID: 29997296.
199. Hurria A, Soto-Perez-de-Celis E, Allred JB, Cohen HJ, Arsenyan A, Ballman K, Le-Rademacher J, Jatoi A, Filo J, Mandelblatt J, Lafky JM, Kimmick G, Klepin HD, Freedman RA, Burstein H, Gralow J, Wolff AC, Magrinat G, Barginear M, Muss H. Functional Decline and Resilience in Older Women Receiving Adjuvant Chemotherapy or Breast Cancer. *J Am Geriatr Soc*. 2018 Aug 26. doi: 10.1111/jgs.15493. [Epub ahead of print] PubMed PMID: 30146695.
200. Beltran H, Oromendia C, Danila DC, Montgomery B, Hoimes C, Szmulewitz RZ, Vaishampayan U, Armstrong AJ, Stein M, Pinski J, Mosquera JM, Sailer V, Bareja R, Romanel A, Gumpeni N, Sboner A, Dardenne E, Puca L, Prandi D, Rubin MA, Scher HI, Rickman DS, Demichelis F, Nanus DM, **Ballman KV**, Tagawa ST. A phase II trial of the aurora kinase A inhibitor alisertib for patients with castration resistant and neuroendocrine prostate cancer: efficacy and biomarkers. *Clin Cancer Res*. 2019 Jan 1;25(1):43-51. pii: clincanres.1912.2018. doi: 10.1158/1078-0432.CCR-18-1912. PubMed PMID: 30232224.
201. Yu H, Chen Z, **Ballman K**, Watson MA, Govindan R, Lanc I, Beer DG, Bueno R, Chirieac L, Chui MH, Chen G, Franklin WA, Gandara DR, Genova C, Brovsky K, Harpole D, Joshi M, Merrick DT, Richards W, Rivard CJ, Tsao MS, van Bokhoven A, Shepherd FA, Hirsch FR. Correlation of PD-L1 expression with tumor mutation burden and gene signatures for prognosis in early stage squamous cell lung carcinoma. *J Thorac Oncol*. 2019 Jan;14(1):25-36. pii: S1556-0864(18)33116-2. doi: 10.1016/j.jtho.2018.09.006. PubMed PMID: 30253973.
202. Tagawa ST, Antonarakis ES, Gjyrezi A, Galletti G, Kim S, Worroll D, Stewart J, Zaher A, Szatrowski TP, **Ballman KV**, Kita K, Tasaki S, Bai Y, Portella L, Kirby BJ, Saad F, Eisenberger MA, Nanus DM, Giannakakou P. Expression of AR-V7 and ARv567es in circulating tumor cells correlates with outcomes to taxane therapy in men with metastatic prostate cancer treated in TAXYNERGY. *Clin Cancer Res*. 2019 Mar 15;25(6):1880-1888. doi: 10.1158/1078-0432.CCR-18-0320. Epub 2018 Oct 9. PMID: 30301829
203. Choy E, **Ballman K**, Chen J, Dickson MA, Chugh R, George S, Okuno S, Pollock R, Patel RM, Hoering A, Patel S. SARC018\_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy. *Sarcoma*. 2018 Oct 24;2018:2068517. doi: 10.1155/2018/2068517. eCollection 2018. PubMed PMID: 30473623; PubMed Central PMCID: PMC6220374.
204. Haffty BG, McCall LM, **Ballman KV**, Buchholz TA, Hunt KK, Boughey JC. Impact of radiation on local regional control in women with node positive breast cancer treated with neoadjuvant chemotherapy and axillary lymph node dissection: Results from ACOSOG 1071 Clinical Trial. *Int J Radiat Oncol Biol Phys*. 2019 May 11. pii: S0360-3016(19)30722-9. doi: 10.1016/j.ijrobp.2019.04.038. [Epub ahead of print] PubMed PMID: 31085287.
205. Younger E, **Ballman K**, Lu Y, Pápai Z, Van Tine BA, Attia S, Schöffski P, Reinke D, Tap WD, Jones RL. Subgroup analysis of older patients treated within the randomized phase 3 doxorubicin versus

doxorubicin plus evofosfamide (SARC021) trial. *J Geriatr Oncol*. 2019 May 21. pii: S1879-4068(18)30464-8. doi: 10.1016/j.jgo.2019.05.008. [Epub ahead of print] PubMed PMID: 31126845.

206. Chatterjee A, Merkler AE, Murthy SB, Burch JE, Chen ML, Gialdini G, Kamel H, **Ballman KV**, Navi BB. Temporal Trends in the Use of Acute Recanalization Therapies for Ischemic Stroke in Patients with Cancer. *J Stroke Cerebrovasc Dis*. 2019 May 29. pii: S1052-3057(19)30229-0. doi: 10.1016/j.jstrokecerebrovasdis.2019.05.009. [Epub ahead of print] PubMed PMID: 31153762.

## 2. Editorials and Letters

1. Ellis M, **Ballman K**. Trawling for genes that predict response to breast cancer adjuvant therapy. *J Clin Oncol*. 2004 Jun 15; 22(12):2267-9. (Editorial) PMID:15136594.
2. Goodwin PJ, **Ballman KV**, Small EJ, Cannistra SA. Evaluation of treatment benefit in Journal of Clinical Oncology. *J Clin Oncol*. 2013 Mar 20; 31(9):1123-4. Epub 2013 Jan 28. PMID:23358984. DOI:10.1200/JCO.2012.47.6952. (Editorial)
3. Sleijfer S, **Ballman K**, Verweij J. The future of drug development? Seeking evidence of activity of novel drugs in small groups of patients. *J Clin Oncol*. 2013 Jun 20; 31(18):2246-8. Epub 2013 Apr 29. PMID:23630203. DOI:10.1200/JCO.2013.48.7645. (Editorial)
4. Nelson H, **Ballman K**. Achieving the right volume of randomized controlled trials. *Ann Surg*. 2013 Aug; 258(2):208-9. PMID:23751450. DOI:10.1097/SLA.0b013e31829c4a05. (Editorial)
5. **Ballman KV**. Phase I trial improvement: a question of patient selection, trial design, or both? *J Clin Oncol*. 2014 Feb 20; 32(6):489-90. Epub 2014 Jan 13. PMID:24419111. DOI:10.1200/JCO.2013.53.6896. (Editorial)
6. Goodwin PJ, **Ballman KV**, Levine M. Twenty-twenty hindsight: an adjuvant breast cancer trial through the retrospectroscope. *J Clin Oncol*. 2014 Aug 1; 32(22):2284-6. Epub 2014 Jun 16. PMID:24934788. DOI:10.1200/JCO.2014.55.9344. (Editorial)
7. Connolly HM, **Ballman KV**, Roger VL, Tajik AJ. Aortic stenosis: no more hemodynamic cardiac catheterization! *Mayo Clin Proc*. 2001 Sep; 76(9):961. PMID:11560311. DOI:10.4065/76.9.961. (Letter)
8. Cooper LT, Tse TS, Mikhail MA, McBane RD, Stanson AW, **Ballman KV**. Long-term survival and amputation risk in Thromboangiitis obliterans (Buerger's disease). *J Am Coll Cardiol*. 2004 Dec 21; 44(12):2410-1. PMID:15607407. (Letter)
9. Giuliano AE, Morrow M, **Ballman KV**. Axillary vs sentinel lymph node dissection for invasive breast cancer. *JAMA*. 2011 Jun 8; 305(22):2290-1. (Letter)
10. Goodwin PJ, **Ballman KV**, Small EJ, Levine M, Cannistra SA. Evaluation of treatment benefit: randomized controlled trials and population-based observational research reply. *J Clin Oncol*. 2013 Sep 10; 31(26):3300. (Letter)
11. **Ballman KV**, Mauer M, Wedding U, Mohile SG, Muss H, Extermann M, Luciani A, Cohen HJ, Hurria A, Lichtman SM, Curigliano G, Wildiers H. Reply to L.K. Mell et al. *J Clin Oncol*. 2014 Apr 1; 32(10):1090-1. Epub 2014 Feb 18. PMID:24550420. DOI:10.1200/JCO.2013.54.5236. (Letter)
12. **Ballman KV**. Reply to D.M. Hyman et al and M. Voskoboynik et al. *J Clin Oncol*. 2014 Oct 1; 32(28):3200. Epub 2014 Jul 28. PMID:25071106. DOI:10.1200/JCO.2014.56.5770. (Letter)
13. **Ballman KV**. Surprising results from an angiotensin-converting enzyme inhibitor trial in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*. 2016; 194(11):1307-1308.
14. **Ballman KV**, McCall LM, Giuliano AE. Axillary vs Sentinel Lymph Node Dissection in Women With Invasive Breast Cancer-Reply. *JAMA*. 2018 Jan 16;319(3):306-307. doi: 10.1001/jama.2017.18318. PubMed PMID: 29340672.
15. Rosenkranz KM, **Ballman K**, McCall L, Kubicky CD, Cuttino L, Le-Petross H, Hunt K, Giuliano A, Van Zee K, Haffty B, Boughey J. Reply to "Can Patients with Multiple Breast Cancers in the Same Breast Avoid Mastectomy by Having Multiple Lumpectomies to Achieve Equivalent Rates of Local Breast Cancer Recurrence? Response to the Preliminary Alliance 11102 Trial Report". *Ann Surg Oncol*. 2019. Feb;26(2):702. doi: 10.1245/s10434-018-6984-6. Epub 2018 Dec 12. PubMed PMID: 30542836.

## 3. Chapters

- 
1. **Ballman KV, Votta L.** Organizational congestion in large-scale software development. Proceedings of the Third International Conference on Software Process, 1994.
  2. **Ballman KV.** Real Data in Classroom Examples. In: Teaching Resources for Undergraduate Statistics. 2000. (Book chapter)
  3. **Ballman KV.** Handbook of Clinical Cancer Research. Springer 2018. (Book chapter)
  4. **Ballman KV.** Predictive Biomarkers in Oncology. Springer 2019. (Book chapter)